Compositions and uses for treating Angelman syndrome - Patent application
Patent Information
- Application Number
- JP2023533671
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-26
- Filing Date
- 2021-12-01
- Publication Date
- 2024-12-09
AI Technical Summary
Current treatments for Angelman syndrome are palliative and do not address the underlying cause, with no cure available for this genetic disorder that causes intellectual disability, motor dysfunction, ataxia, aphasia, and severe seizures.
A novel adeno-associated virus (AAV)-based gene replacement therapy is developed to deliver a functional UBE3A-isoform 1 protein to neurons, using a recombinant AAV vector with a neuron-specific promoter to restore UBE3A expression in individuals with Angelman syndrome.
The therapy effectively alleviates motor and behavioral deficits associated with Angelman syndrome by restoring UBE3A protein levels in neurons, improving symptoms such as developmental delay, intellectual disability, ataxia, and epilepsy in animal models.
Smart Images

Figure 00000051_0000 
Figure 00000051_0001 
Figure 00000051_0002
Abstract
Description
[Background technology]
[0001] Angelman syndrome (AS) is a rare genetic disorder affecting 500,000 people worldwide. The main symptoms of AS include intellectual disability, motor impairment, ataxia, aphasia, severe seizures, and characteristic behavioral traits. Most individuals with AS exhibit loss of function of the maternally inherited UBE3A allele, which encodes the HECT E3 ubiquitin ligase that ligates ubiquitin to a substrate for degradation. 65–70% of AS cases result from class I mutations, including de novo deletions of maternal chromosomes 15q11–q13 [Angelman H., Puppet' children. A report on three cases, Dev Med Child Neurol, 1965, 7:681-88; Mertz LG et al., Angelman syndrome in Denmark. Birth incidence, genetic findings, and age at diagnosis, Am J Med Genet A, 2013, 161A(9):2197-2203, epub August 2, 2013; Clayton-Smith J., and Laan L., Angelman syndrome:a review of the clinical and genetic types,J Med Genet,2003,40(2):87-95,pub February 1,2003,Khatri N and Man H,The Autism and Angelman Syndrome Protein Ube3A / E6AP:The Gene,E3 Ligase Ubiquination Targets and Neurobiological Functions,Front Mol Neurosci,2009,12(109):1-12,epub April 30,2019].
[0002] Three UBE3A isoforms in mouse are described, and isoforms 2 and 3 are identified as the major UBE3A splice variants in mouse. (Valluy, J. et al., A coding-independent function of an alternative Ube3a transcript during neuronal development,Nat Neurosci,2015,18(5):666-673,epub April 13,2015, Trezza RA et al.,Loss of nuclear UBE3a causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome,Nat Neurosci,2019,22(8):1235-1247,epub June 24,2019,Zampeta FI et al.,Conserved UBE3a subcellular distribution between human and mice is facilitated by non-homologous isoforms,Hum Mol Genet,2020,29(18):3032-3043,epub (September 2, 2020). Loss of hUBE3A isoform 1 occurs in individuals with "mild" Angelman syndrome (Sadhwani, A et al., Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3a isoform, Am J Med Genet A, 2018, 176(7):1641-1647, epub May 7, 2018), still nuclear hUB It expresses E3A isoform 3 and cytoplasmic hUBE3A isoform 2.
[0003] Currently, there is no cure for AS. Current treatments are palliative and focus on managing medical problems, including seizures, and issues related to progression. The lack of treatment options highlights a significant unmet need for new treatments for AS. [Overview of the project]
[0004] A novel adeno-associated virus (AAV)-based gene replacement therapy, based on UBE3A-isoform 1, is provided herein. The composition and method can mitigate motor and behavioral defects associated with Angelman syndrome (AS), as evaluated in an animal model of Angelman. In one embodiment, the composition comprises a stock of recombinant adeno-associated virus (rAAV) useful for the treatment of AS, wherein the rAAV comprises an AAV capsid and a vector genome packaged therein, the vector genome comprising (a) an AAV5' inverted terminal repeat (ITR), (b) SEQ ID NO: 9, or a sequence encoding a UBE3A isoform 1 protein that is 95% identical thereto (SEQ ID NO: 2), the UBE3A nucleic acid sequence, wherein the nucleic acid is operably linked to a regulatory element that modulates the expression of the UBE3A protein in human cells, (c) a regulatory element that directs the expression of UBE3A of (b), and (d) an AAV3'ITR. In a particular embodiment, the regulatory element comprises a neuron-specific promoter. In certain embodiments, the neuron-specific promoter is a synapsin promoter. In certain embodiments, the synapsin promoter is a shortened promoter having the nucleic acid sequence of SEQ ID NO: 12. In certain embodiments, the regulatory element includes a constitutive promoter. In certain embodiments, the regulatory element further includes one or more enhancers and one or more introns. In certain embodiments, the regulatory sequence further includes one or more targeting sequences of miR182 (SEQ ID NO: 20) and / or miR183 (SEQ ID NO: 11), the targeting sequences being operably linked to the UBE3A nucleic acid sequence. In certain embodiments, the regulatory sequence further includes one or more targeting sequences of miR selected from miR182 and / or miR183, the targeting sequences being located downstream of the UBE3A nucleic acid sequence. In certain embodiments, the regulatory sequence further includes four targeting sequences of miR183, the targeting sequences being located downstream of the UBE3A nucleic acid sequence. In certain embodiments, the regulatory sequence includes four copies of SEQ ID NO: 11. In a particular embodiment, the AAV capsid is the AAVhu68 capsid.In certain embodiments, the AAV capsid is the AAVhu68 capsid produced from the expression of the nucleic acid sequence of SEQ ID NO: 14 or SEQ ID NO: 16. In certain embodiments, the AAV capsid is the AAVrh91 capsid. In certain embodiments, the AAV capsid is the AAVrh91 capsid expressed from the nucleic acid sequence of SEQ ID NO: 17 or SEQ ID NO: 19. In certain embodiments, the composition is an aqueous suspension further comprising a physiologically suitable carrier, buffer, adjuvant, and / or diluent.
[0005] In certain embodiments, the compositions described herein are useful for use in the treatment of patients with Angelman syndrome. In certain embodiments, the compositions provided herein are useful for the treatment of one or more symptoms of Angelman syndrome, optionally selected from one or more of the following: developmental delay, intellectual disability, severe speech disorder, ataxia, and / or epilepsy. In certain embodiments, a method is provided for treating one or more symptoms of Angelman syndrome (AS) in patients with a deficiency of UBE3A expression in neurons via delivery of an expression cassette provided herein. In certain embodiments, the expression cassette treats a symptom selected from one or more of the following: developmental delay, intellectual disability, severe speech disorder, ataxia, and / or epilepsy. In certain embodiments, the compositions are provided for intrathecal delivery to the patient. In certain embodiments, the patient receives at least 1 × 10⁻⁶ 10 ~1 × 10 13 GC / kg manipulated UBE3A code sequence The patient is injected with the rAAV that will be carried by the patient.
[0006] In certain embodiments, the method provides improvement of symptoms of Angelman disorder, including one or more of developmental delay, intellectual disability, severe speech impairment, ataxia, and / or epilepsy.
[0007] Other aspects and advantages of these methods and compositions will be further described in the following detailed description. [Brief explanation of the drawing]
[0008] [Figure 1A-1C] This document provides schematic diagrams of miR sequence-free expression cassettes and vector genomes for regulating dorsal root ganglion expression and toxicity. Figure 1A provides a schematic diagram of the vector genome in which a 5'AAV inverted terminal repeat (ITR) and a 3'AAV ITR adjoin the hUBE3A-isoform 1 expression cassette. The expression cassette contains an engineered hUBE3A-isoform 1 coding sequence (encoding 852 amino acids; SEQ ID NO: 2) under the control of a modified synapsin promoter. The hUBE3A coding sequence includes the amino-terminal zinc finger of the Ube3A ligase (AZUL), the HECT domain and RCC1-like domain 2 (HERC2), the E6 protein-binding domain (E6BD), and the E6-AP carboxyl-terminal homologous region (HECT), as well as SV40 polyA. Figure 1B provides a schematic diagram of the vector genome in which an AAV ITR adjoins the hUBE3A-isoform 2 expression cassette. The encoded isoform 2 protein is 875 amino acids long (SEQ ID NO: 6). Figure 1C provides a schematic diagram of the vector genome, with the AAV ITR adjacent to the hUBE3A-isoform 3 expression cassette. The encoded isoform 3 protein is 872 amino acids long (SEQ ID NO: 21). [Figure 2A-2B]Figure 2A shows the results of evaluating the biodistribution and mRNA expression of rAAVhu68.UBE3A-isoform 1 vectors in non-human primates (NHPs), specifically those containing four copies of the miR183 (4xmiR183) target sequence (light circles) or those not containing the 4xmiR183 sequence (bold sequences). Figure 2A shows the biodistribution of UBE3A isoform 1 vectors in NHPs, measured using genome copy (GC) / diploid genomes in the cerebellum, caudate nucleus, hippocampus, frontal cortex, occipital cortex, medulla, parietal cortex, temporal cortex, thalamus, cervical spinal cord DRG, thoracic spinal cord DRG, lumbar spinal cord DRG, cervical spinal cord, thoracic spinal cord, and lumbar spinal cord. Figure 2B shows UBE3A isoform 1 mRNA expression in the spinal cord and DRG of NHP patients after treatment with rAAVhu68.UBE3A-isoform 1, either containing four copies of the miR183 (4xmiR183) target sequence (light circles) or not containing the 4xmiR183 sequence (dark sequences). Figure 2C shows UBE3A isoform 1 in the cerebellum, caudate nucleus, hippocampus, frontal cortex, occipital cortex medulla, parietal cortex, temporal cortex, thalamus, cervical spinal cord DRG, thoracic spinal cord DRG, lumbar spinal cord DRG, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, and cerebrum (negative control). [Figure 3A-3B] This study demonstrates that the AAVhu68-UBE3A-isoform1±4xmiR183 vector does not induce significant dorsal root ganglion (DRG) toxicity in rhesus monkeys (3-4 years old). The hUBE3A-1 (group 1) or hUbe3a-1-4xmiR183 (group 2) vectors do not induce significant AAV-induced dorsal root ganglion toxicity in rhesus monkeys 35 days after administration to the cisterna magna (ICM) at a dose of 3 × 10¹³ GC / animal. DRG-related toxicity was observed only in the spinal cord and peripheral nerves of 192,285 animals in group 1. Across both groups, the animal DRGs were normal (Figure 3A), with only sporadic, minimal mononuclear cell infiltration (Figure 3B, circled), and no evidence of neurodegeneration (3 / 3 animals, group 1; 3 / 3 animals, group 2). [Figure 4A-4B]This shows the effects of rAAVhu68.synapsin-UBE3A isoform 1 on the peripheral nerves of rhesus monkeys (3-4 years old). Minimal focal axonal damage in hindlimb nerves (arrows). Figure 4A shows animal AAVhu68.synapsin-UBE3A isoform 1 on the peripheral nerves. Figure 4B shows that animals 192275 and 192297 exhibited mild multifocal axonal damage (arrows) and mononuclear cell infiltration (oval) in the right median nerve of the forelimb, as did animal 192285. [Figure 5] This report quantifies UBE3A protein-positive neurons in treated UBE3Am- / p+ neonatal mice. Treatment consisted of intraventricular (ICV) administration of AAV-PHP.B-hSyn-UBE3A-isoform 1 at a dose of 1 × 10¹¹ GC / animal. In the cortex, hippocampus, thalamus, hypothalamus, and midbrain, 42–68% of neurons expressed UBE3A protein (normalized to UBE3A-positive neurons in their respective WT tissues). [Figure 6] This report quantifies UBE3A protein-positive neurons in treated UBE3Am- / p+ neonatal mice. Treatment included administration of AAV-PHP.B-hSyn-UBE3A-isoform 1 at a dose of 1 × 10¹⁰ GC / animal via intraventricular ventricle (ICV). In the cortex, hippocampus, thalamus, hypothalamus, and midbrain, 20–50% of neurons expressed UBE3A protein (normalized to UBE3A-positive neurons in their respective WT tissues). [Figure 7A-7I]Fluorescence images of engineered human UBE3A isoform 1 (hUBE3A-1) transcript localization in the dorsal root ganglia (cervical, thoracic, and lumbar segments) of three treated non-human primate-derived animals (NHP-1, -2, -3; 35-day study) are shown. Treatment included administration of AAV-PHP.B-hSyn-UBE3A-isoform 1 at a dose of 3 × 10¹³ GC / animal via the cisterna magna (ICM) pathway. Images of the region of interest were taken at various magnifications, and the 20x magnification image is shown. Figure 7A shows fluorescence images of engineered hUBE3A-1 transcript localization in the cervical segment of the dorsal root ganglia derived from NHP-1. Figure 7B shows fluorescence images of engineered hUBE3A-1 transcript localization in the cervical segment of the dorsal root ganglia derived from NHP-2. Figure 7C shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the cervical spinal segment of the dorsal root ganglion derived from NHP-3. Figure 7D shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the thoracic spinal segment of the dorsal root ganglion derived from NHP-1. Figure 7E shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the thoracic spinal segment of the dorsal root ganglion derived from NHP-2. Figure 7F shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the thoracic spinal segment of the dorsal root ganglion derived from NHP-3. Figure 7G shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the lumbar spinal segment of the dorsal root ganglion derived from NHP-1. Figure 7H shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the lumbar spinal segment of the dorsal root ganglion derived from NHP-2. Figure 7I shows fluorescence images of manipulated hUBE3A-1 transcript localization in the lumbar spinal segment of the dorsal root ganglion derived from NHP-3. [Figure 8] This shows the expression of the manipulated UBE3A isoform 1 in the brains of UBE3Am- / p+ and wild-type mice after ICV injection using AAV-PHP.B-hSyn-hUBE3A-iso1. [Figure 9A-9B]Figure 9A shows the results of motor coordination behavior tests performed at 8-10 weeks of age in neonatal wild-type or AS (UBE3Am- / p+) mice after intraventricular (ICV) injection of either the AAV-PHP.B-synapsin-UBE3A-isoform 1 or isoform 2 vector at a dose of 1 × 10¹¹ genome copies (GC) per animal. Figure 9B shows the motor coordination in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. [Figure 10A-10D] The results of nest-building ability behavior tests conducted at 8-10 weeks of age in neonatal wild-type or AS (UBE3Am- / p+) mice after intraventricular (ICV) injection of either the AAV-PHP.B-synapsin-UBE3A-isoform 1 or isoform 2 vector at a dose of 1 × 10¹¹ genome copies (GC) per animal are shown. Figure 10A shows the nest-building scores in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. Figure 10B shows the percentage of unused nest material in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. Figure 10C shows the nest-building scores in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 2. Figure 10D shows the percentage of unused nesting material in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 2. [Figure 11A-11D]The results of catwalk (gait length and gait improvement) behavior tests conducted at 8-10 weeks of age in neonatal wild-type or AS(UBE3Am- / p+) mice after intraventricular (ICV) injection of the AAV-PHP.B-synapsin-UBE3A-isoform 1 vector at a dose of 1 × 10¹¹ genome copies (GC) per animal are shown. Figure 11A shows the gait length of the right hind (RH) limb in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. Figure 11B shows the gait length of the left hind (LH) limb in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. Figure 11C shows the gait length of the right hind (RH) limb in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. Figure 11D shows the left hind limb length in WT and AS mice after treatment with AAV-PHP.B-synapsin-UBE3A-isoform 1. [Figure 12A-2C] The results of toxicity studies in the dorsal root ganglia (DRGs) of NHP 35 days after treatment with AAV-hu68-hSyn-UBE3A-isoform 1 at a dose of 3 × 10¹³ GC / animal via the cisterna magna (ICM) pathway are shown (pathological grades are plotted on a scale of 0 to 5). Figure 12A shows the scored pathological grades in the cervical spinal cord segment of the DRGs of NHP. Figure 12B shows the scored pathological grades in the thoracic spinal cord segment of the DRGs of NHP. Figure 12C shows the scored pathological grades in the lumbar spinal cord segment of the DRGs of NHP. [Figure 13A-13C] The results of toxicity studies in the spinal cord of NHP patients 35 days after treatment with AAV-hu68-hSyn-UBE3A-isoform 1 at a dose of 3 × 10¹³ GC / animal via the cisterna magna (ICM) pathway are shown (pathological grades are plotted on a scale of 0 to 5). Figure 13A shows the scored pathological grades in the cervical spinal cord segment of NHP patients. Figure 13B shows the scored pathological grades in the thoracic spinal cord segment of NHP patients. Figure 13C shows the scored pathological grades in the lumbar spinal cord segment of NHP patients. [Figure 14] The results of a peripheral nerve toxicity study of NHP 35 days after treatment with AAV-hu68-hSyn-UBE3A-isoform 1 at a dose of 3 × 10¹³ GC / animal via the cisterna magna (ICM) pathway are shown (axonal degeneration pathology grades were scored from 0 to 5 and plotted). [Figure 15A-15C] Figure 15A shows the results of peripheral nerve conduction studies 14 and 35 days after treatment with AAV-hu68-hSyn-UBE3A-isoform 1 at a dose of 3 × 10¹³ GC / animal via the cisterna magna (ICM) pathway. Figure 15A shows the velocity of the left median nerve as measured in m / s. Figure 15B shows the results of peripheral nerve conduction studies 14 and 35 days after treatment with AAV-hu68-hSyn-UBE3A-isoform 1, measured in peak-to-peak (PP) amplitude in mV units. Figure 15C shows the results of peripheral nerve conduction studies 14 and 35 days after treatment with AAV-hu68-hSyn-UBE3A-isoform 1, measured in negative peak (NP) amplitude in mV units. [Figures 16A-16B] Figure 16A shows the quantification of UBE3A isoform 1 or isoform 2 protein-positive neurons in treated UBE3Am- / p+ neonatal mice, plotted as the percentage of positive neurons in the cortex, hippocampus, thalamus, hypothalamus, and midbrain, normalized to UBE3A-positive neurons in WT tissue. Treatment included administration of AAV-PHP.B-hSyn-UBE3A-isoform 1 or isoform 2 at a dose of 1 × 10¹¹ GC / animal via intraventricular (ICV). Figure 16A shows the percentage of UBE3A isoform 1-positive neurons in the cortex, hippocampus, thalamus, hypothalamus, and midbrain of treated mice. Figure 16B shows the percentage of UBE3A isoform 2-positive neurons in the cortex, hippocampus, thalamus, hypothalamus, and midbrain of treated mice. [Modes for carrying out the invention]
[0009] Provided herein is an expression cassette containing an engineered UBE3A-isoform 1 coding sequence that, when delivered (e.g., via rAAV-mediated gene replacement therapy), expresses UB3A isoform 1 at a level that treats the symptoms of Angelman syndrome. In certain embodiments, the regulatory elements in the expression cassette include up to eight, e.g., four to eight miR183 sequences, to modulate dorsal root ganglion (DRG) expression and / or toxicity. In certain embodiments, these DRG detargeting sequences are selected for use when high levels of expression and / or systemic delivery are intended. In other embodiments, these sequences are included when intrathecal delivery is utilized.
[0010] In one embodiment, the expression cassette includes an engineered UBE3A code (nucleic acid sequence) that is operably linked to a regulatory element that modulates the expression of the UBE3A protein in target human cells. In a particular embodiment, the UBE3A coding sequence codes for the UBE3A isoform 1 protein and is reproduced in Sequence ID No. 2. The UBE3A isoform 1 protein includes several domains, including the amino-terminal zinc finger of the Ube3A ligase (AZUL), the HECT domain and RCC1-like domain 2 (HERC2), the E6 protein-binding domain (E6BD), and the E6-AP carboxyl-terminal homology region (HECT). Preferably, the engineered UBE3A isoform 1 coding sequence is the nucleic acid sequence of Sequence ID No. 9, or a sequence encoding the UBE3A isoform 1 protein that is at least 95% identical thereto (Sequence ID No. 2). In a particular embodiment, the sequence is 100% identical to the full-length Sequence ID No. 9. In other embodiments, the sequence is at least 95%, at least 97%, at least 98%, at least 99%, and 99.5% identical to sequence number 9. In certain embodiments, the UBE3A isoform 1 coding sequence is cleaved at its 5' or 3' end, resulting in carboxyl or N-terminal cleavage of the UBE3A isoform 1 protein.
[0011] In certain embodiments, the UBE3A coding sequence encodes the UBE3A isoform 2 protein, which is reproduced in Sequence ID No. 6. The UBE3A isoform 2 protein comprises several domains, including the amino-terminal zinc finger of Ube3A ligase (AZUL), the HECT domain and RCC1-like domain 2 (HERC2), the E6 protein-binding domain (E6BD), and the E6-AP carboxyl-terminal homology region (HECT). Preferably, the manipulated UBE3A isoform 2 coding sequence is the nucleic acid sequence of Sequence ID No. 10, or a sequence encoding the UBE3A isoform 2 protein that is at least 95% identical thereto (Sequence ID No. 6). In certain embodiments, the sequence is 100% identical to the full-length Sequence ID No. 10. In other embodiments, the sequence is at least 95% identical, at least 97% identical, at least 98% identical, at least 99% identical, or 99.5% identical to Sequence ID No. 10. In certain embodiments, the UBE3A isoform 2 coding sequence is cleaved at its 5' or 3' end, resulting in carboxyl or N-terminal cleavage of the UBE3A isoform 2 protein. In certain embodiments, the UBE3a coding sequence encoding the UBE3A isoform 3 protein is reproduced in Sequence ID No: Q05086-3.
[0012] In certain embodiments, the expression cassette comprises a UBE3A coding sequence, optionally encoding a fusion protein comprising a signal peptide and a functional UBE3A protein. The expression cassette encodes a fusion protein containing an uptake peptide fused to a UBE3A coding sequence. In certain embodiments, optionally, the UBE3A coding sequence encodes a fusion protein containing a UBE3A protein fused to a signal peptide and / or uptake peptide. In some embodiments, the expression cassette contains a UBE3A coding sequence, and optionally, the signal peptide and / or uptake peptide is located at either the 5' or 3' of the UBE3A coding sequence, resulting in a fusion protein containing a signal peptide and / or uptake peptide at the N-terminus of the UBE3A protein, a fusion protein containing a signal peptide and / or uptake peptide at the C-terminus of the UBE3A protein, or a fusion protein containing a signal peptide or uptake peptide at the C-terminus of the UBE3A protein, or a combination thereof. In certain embodiments, the signal peptide is a conjugated immunoglobulin protein (BiP) signal peptide. In certain embodiments, the signal peptide is a Gaussia signal peptide. See also U.S. Patent No. 9,279,007B2 (corresponding International Patent Application No. 2012 / 071422, Binding Immunoglobulin Protein (BiP) Signal Peptide) and U.S. Patent No. 10,874,750B2 (corresponding International Patent Application No. 2019 / 213180A1, Binding Immunoglobulin Protein (BiP) Signal Peptide and Gaussia Signal Peptide), which are incorporated herein by reference in their entirety. In certain embodiments, optionally, UBE3A is a fusion protein comprising a peptide that enhances expression, secretion, and cellular uptake. In certain embodiments, optionally, UBE3A is a fusion protein comprising a peptide that is a cystatin peptide sequence. See also U.S. Patent No. 9,567,369, which is incorporated herein by reference in its entirety. In certain embodiments, optionally, UBE3A is a fusion protein comprising a peptide that is a derivative from HIV TATk peptides (e.g., TATk28, TATk11).See also WO2015 / 128746A2 (US10,907,138B2), WO2018 / 005617A2 (US2021 / 0268072), WO2019 / 108924A2, WO2020 / 250081A1, and WO2021 / 087282A1, which are incorporated herein by reference in their entirety. In certain embodiments, the peptide is the IGF2 peptide. See also WO2021 / 072372, which is incorporated herein by reference in its entirety. In certain embodiments, optionally, UBE3A is a fusion protein comprising a peptide containing a cell uptake sequence selected from penetratin, R6W3, HIV TAT, HIV TATk, and pVEC. In certain embodiments, UBE3A is a fusion protein comprising a peptide containing secretion sequences selected from insulin, GDNF, and IgK. See also WO2019 / 006107, which is incorporated herein in its entirety by reference.
[0013] In certain embodiments, the UBE3A isoform 1 expression cassette is selected for delivery as gene replacement therapy alone. In certain embodiments, the UBE3A isoform 1 expression cassette is selected for delivery as gene replacement therapy in a regimen (e.g., short-term or long-term enzyme replacement therapy and / or substrate depletion therapy) that includes one or more other active ingredients.
[0014] In one embodiment, the composition comprises a vector containing an expression cassette of UBE3A isoform 1. Suitable vectors and vector genomes are described herein.
[0015] In other embodiments, a stock of recombinant parvovirus vectors (e.g., recombinant adeno-associated virus) is provided. rAAV comprises an AAV capsid and a vector genome packaged therein, wherein the vector genome is a UBE3A nucleic acid sequence comprising (a) an AAV 5' inverted terminal repeat (ITR), (b) SEQ ID NO: 9, or a sequence encoding a UBE3A isoform 1 protein that is 95% identical thereto (SEQ ID NO: 2), and The AAV capsid comprises (c)(b) a UBE3A nucleic acid sequence, (c)(b) a regulatory element that directs the expression of UBE3A, and (d) an AAV3'ITR, which are operablely linked to a regulatory element that regulates the expression of the UBE3A protein in human cells. The desired AAV capsids include AAVhu68 and AAVrh91 that target desired cells in the central nervous system (CNS).
[0016] In certain embodiments, rAAV comprises an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises (a) an AAV5' inverted terminal repeat (ITR), (b) optionally a peptide (e.g., a signal or uptake peptide), (c) a UBE3A nucleic acid sequence comprising SEQ ID NO: 9 or a sequence encoding a UBE3A isoform 1 protein that is 95% identical thereto (SEQ ID NO: 2), wherein the nucleic acid sequence is operably linked to a regulatory element that regulates the expression of the UBE3A protein in human cells, (d) optionally a peptide (regulatory and / or uptake peptide), (e) a regulatory element that directs the expression of UBE3A in (b), and (f) an AAV3'ITR. In certain embodiments, the signal peptide is a BiP signal peptide. See also US9,279,007B2 (corresponding International Patent Application No. 2012 / 071422) and US10,874,750B2 (corresponding International Patent Application No. 2019 / 213180A1), which are incorporated herein by reference in their entirety. In certain embodiments, the regulatory peptide is an IGF peptide. See also WO2021 / 072372, which is incorporated herein by reference in its entirety. In certain embodiments, the signal peptide is a secretory signal peptide comprising a secretory sequence selected from insulin, GDNF, and IgK. In certain embodiments, penetratin, R6W3, HIV An uptake peptide comprising a cell uptake sequence selected from TAT, HIV TATk, and pVEC. See also WO2019 / 006107, which is incorporated herein in its entirety by reference.
[0017] In certain embodiments, UBE3A is a fusion protein comprising, optionally, a signal peptide and / or an incorporation peptide as described herein. In certain embodiments, the signal peptide and / or incorporation peptide is located at either the amino(N) terminus or the carboxy(C) terminus. In certain embodiments, the signal peptide is located at the amino(N) terminus. In certain embodiments, the incorporation peptide is located at either the N-terminus or the C-terminus.
[0018] As used herein, a “stock” of rAAVs refers to a population of rAAVs. Despite the heterogeneity of capsid proteins resulting from deamidation, rAAVs within a stock are expected to share five identical vector genomes. A stock may include, for example, rAAVs having a selected AAV capsid protein and capsids with heterogeneous deamidation patterns characteristic of a selected production system. A stock may be produced from a single production system or pooled from multiple runs of a production system. A variety of production systems may be selected, including but not limited to those described herein.
[0019] Unless otherwise defined herein, the technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention pertains, and by referring to published documents that provide general guidance to those skilled in the art for many of the terms used herein.
[0020] As used herein, “disease,” “disorder,” and “condition” are used interchangeably to describe an abnormal condition in the subject. In one embodiment, the disease is Angelman syndrome (AS).
[0021] As used herein, “patient” or “subject” refers to a human, a veterinary animal, or an agricultural animal. This interchangeably means male or female mammals, including animals, domestic animals or pets, and animals typically used in clinical research. In one embodiment, the subjects of these methods and compositions are human patients. In one embodiment, the subjects of these methods and compositions are male or female humans.
[0022] As used throughout this specification and the claims, the terms “comprising,” “containing,” and “including,” and their variations thereto, include other components, elements, integers, steps, etc. Conversely, the term “consisting,” and its variations thereto, exclude other components, elements, integers, steps, etc.
[0023] Please note that the terms "a" or "an" refer to one or more; for example, "a neuron" is understood to represent one or more neurons. Therefore, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably in this specification.
[0024] Where used herein, the term "about" means a variation of plus or minus 10% from the given reference, unless otherwise specified.
[0025] In certain cases, the term "E+#" is used to refer to an exponent. For example, 5E10 means 5 × 10 10 These terms can be used interchangeably.
[0026] The nucleic acid sequences described herein can be cloned using conventional molecular biology techniques or generated de novo by DNA synthesis. The nucleic acid sequences encoding the embodiments of the UBE3A gene described herein are assembled and placed in any suitable gene element, e.g., naked DNA, phages, transposons, cosmids, episomes, etc., to introduce the sequence, which is supported thereon, into a host cell, for example, to generate a non-viral delivery system (e.g., an RNA-based system, naked DNA, etc.), or to generate a viral vector within a packaging host cell and / or to deliver it to a target host cell. In one embodiment, the gene element is a vector. In one embodiment, the gene element is a plasmid. Methods used to construct such engineered constructs are known to those skilled in the art of nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthesis techniques. See, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (2012).
[0027] Expression cassette As used herein, “expression cassette” refers to a nucleic acid molecule comprising a biologically useful nucleic acid sequence and regulatory sequences operably linked to it that direct or regulate the transcription, translation, and / or expression of the nucleic acid sequence (e.g., a gene cDNA encoding a protein, enzyme, or other useful gene product, such as mRNA) and the gene product. As used herein, “operably linked” sequences include both regulatory sequences that are continuous or discontinuous with the nucleic acid sequence and regulatory sequences that act in trans or cis nucleic acid sequences. Such regulatory sequences typically include, for example, one or more of the following: promoters, enhancers, introns, Kozak sequences, polyadenylation sequences, and TATA signals. Among other elements, an expression cassette may also contain one or more upstream (5'~) regulatory sequences of the gene sequence, such as promoters, enhancers, and introns, and one or more enhancers or downstream (3'~) regulatory sequences of the gene sequence, such as a 3' untranslated region (3'UTR) containing a polyadenylation site. In a particular embodiment, the regulatory sequence is operably linked to the nucleic acid sequence of the gene product, and the regulatory sequence is interposed to the nucleic acid sequence, i.e., the 5' unflipped portion. The translation region (5'UTR) separates the nucleic acid sequence of the gene product. In certain embodiments, the expression cassette contains the nucleic acid sequences of one or more gene products. In some embodiments, the expression cassette may be a monocistronic or bicistronic expression cassette. In other embodiments, the term “transgene” refers to one or more DNA sequences from an exogenous source that are inserted into a target cell. Typically, such an expression cassette can be used to generate a viral vector and contains the coding sequence of the gene product described herein, adjacent to the packaging signal of the viral genome, and other expression regulatory sequences, such as those described herein. In certain embodiments, the vector genome may contain two or more expression cassettes.
[0028] In some embodiments, the nucleic acid molecule containing the coding sequence is the UBE3A coding sequence, and may further contain a promoter and other regulatory sequences thereof. In certain embodiments, the expression cassette is used to generate a viral vector (e.g., a viral particle) and contains the UBE3A coding sequence described herein, and other expression regulatory sequences such as those described herein, adjacent to the packaging signal of the viral genome. In some embodiments, the viral vector is an AAV viral vector, and the packaging signal is a 5'AAV inverted terminal repeat (ITR) and a 3'AAV ITR. Optionally, the expression cassette (and vector genome) may contain one or more drg-miRNA targeting sequences in the UTR to reduce, for example, dorsal root ganglion (DRG) toxicity and / or axonal degeneration. For example, see PCT / US2019 / 67872, filed on December 20, 2019, and currently published as WO2020 / 132455; U.S. Provisional Patent Application No. 63 / 023593, filed on May 12, 2020; and U.S. Provisional Patent Application No. 63 / 038488, filed on June 12, 2020, all of which are titled “Compositions for Drg-Specific Reduction of Transgene Expression,” and are incorporated herein by reference in their entirety.
[0029] As used herein, the terms “operably linked” or “operably associated” refer to both an expression regulatory sequence or regulatory element that is continuous with the gene of interest, and an expression regulatory sequence that controls the gene of interest either in trans or detached from it.
[0030] Where used herein, regulatory elements include, but are not limited to, promoters, enhancers, transcription factors, transcription termination factors, efficient RNA processing signals such as splicing and polyadenylation signals (poly-A), sequences that stabilize cytoplasmic mRNA, such as woodchuck hepatitis virus (WHP) posttranscriptional regulators (WPRE), and sequences that improve translation efficiency (i.e., Kozak consensus sequences).
[0031] In one embodiment, the expression cassette includes a regulatory element that directs the expression of sequences encoding one or more elements of a gene substitution system for delivering UBE3A. In one embodiment, the regulatory element includes one or more promoters. In a particular embodiment, the expression cassette includes a constitutive promoter or a regulatory promoter. In a particular embodiment, the promoter is a tissue-specific (e.g., neuron-specific) promoter. In a particular embodiment, preferred promoters include, but are not limited to, the elongation factor 1 alpha (EF1 alpha) promoter (e.g., Kim DW et al, Use of the human elongation factor 1 alpha promoter). as a versatile and efficient expression See system.Gene.1990 Jul 16;91(2):217-23, synapsin 1 promoter (e.g., Kugler S et al, Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene) See "Expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 2003 Feb;10(4):337-47," abbreviated synapsin promoters such as those provided in the examples herein (e.g., see SEQ ID NO: 12 for the coding sequence), neuron-specific enolase (NSE) promoters (e.g., Kim J et al, "Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology. 2004 Feb;145(2):613-9. Epub 2003 Oct 16"), or CB6 promoters (e.g., "Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene," Mol Biotechnol. 2016). See Jan;58(1):30-6.doi:10.1007 / s12033-015-9899-5. Other suitable promoters include the CAG promoter, which comprises (C) the initial enhancer element of cytomegalovirus (CMV), (A) the promoter, the first exon and first intron of the chicken beta-actin gene, and (G) the splice acceptor of the rabbit beta-globin gene. See, for example, Alexopoulou, Annika N., et al. BMC cell biology 9.1(2008):2. Less preferably, other promoters such as viral promoters, constitutive promoters, inducible promoters, and regulatory promoters (see, for example, WO2011 / 126808 and WO2013 / 04943), or promoters that respond to physiological cues may be used in the vectors described herein.In one particular embodiment, the expression cassette includes a U6 promoter. In another embodiment, the regulatory element includes an enhancer. In yet another embodiment, the enhancer is selected from one or more of the following: APB enhancer, ABPS enhancer, alpha-mic / bik enhancer, TTR enhancer, en34 enhancer, ApoE enhancer, CMV enhancer, or RSV enhancer. In yet another embodiment, the regulatory element includes an intron. In yet another embodiment, the intron is selected from CBA, human beta-globulin, IVS2, SV40, bGH, alpha-globulin, beta-globulin, collagen, ovalbumin, or p53. In one embodiment, the regulatory element includes polyA. In yet another embodiment, polyA is synthetic polyA, or from bovine growth hormone (bGH), human growth hormone (hGH), SV40 (see, for example, SEQ ID NO: 13 for the coding sequence), rabbit β-globin (RGB), or modified RGB (mRGB), as provided in the examples herein. In another embodiment, the modulating element may include a WPRE sequence. In yet another embodiment, the modulating element may include a Kozak sequence.
[0032] In certain embodiments, the expression cassette includes a sequence encoding UBE3A that includes the nucleic acid sequence of SEQ ID NO: 22, or at least about 90% identical thereto, the amino acid sequence of SEQ ID NO: 2. In certain embodiments, the expression cassette includes a sequence encoding UBE3A that includes the nucleic acid sequence of SEQ ID NO: 23, or at least about 90% identical thereto, the amino acid sequence of SEQ ID NO: 4. In certain embodiments, the expression cassette includes a sequence encoding UBE3A that includes the nucleic acid sequence of SEQ ID NO: 24, or at least about 90% identical thereto, the amino acid sequence of SEQ ID NO: 6. In certain embodiments, the expression cassette includes a sequence encoding UBE3A that includes the nucleic acid sequence of SEQ ID NO: 25, or at least about 90% identical thereto, the amino acid sequence of SEQ ID NO: 8.
[0033] The term “expression” is used herein in its broadest sense and includes the production of RNA, the production of proteins, or the production of both RNA and proteins. With respect to RNA, the terms “expression” or “translation” are used in particular with respect to the production of peptides or proteins. Expression can be transient or stable.
[0034] The expression cassette can be delivered via any suitable delivery system. Suitable nonviral delivery systems are known in the art (e.g., Ramamoorth and Narvekar. J Clin Diagn Res. 2015 Jan;9(1):GE01-GE06, incorporated herein by reference) and can be readily selected by those skilled in the art, and may include, for example, naked DNA, naked RNA, dendrimers, PLGA, polymethacrylate, inorganic particles, lipid particles (lipid nanoparticles or LNPs), or chitosan-based formulations.
[0035] In one embodiment, the vector is a nonviral plasmid and includes the expression cassette described herein, e.g., “Naked DNA”, “Naked Plasmid DNA”, RNA, and mRNA, conjugated to a variety of compositions and nanoparticles, including, for example, micelles, liposomes, cationic lipid-nucleic acid compositions, polyglycan compositions, and other polymers, lipids, and / or cholesterol-based nucleic acid conjugates, and other constructs such as those described herein. See, for example, X. Su et al, Mol. Pharmaceuticals, 2011, 8(3), pp 774-787, published online: March 21, 2011, WO2013 / 182683, WO2010 / 053572, and WO2012 / 170930, all of which are incorporated herein by reference.
[0036] Provided herein are compositions comprising nucleic acid sequences encoding one or more elements of a gene replacement system, and methods for using the same to replace functional UBE3A.
[0037] Optionally, the expression cassette may include a miRNA target sequence in its untranslated region. The miRNA target sequence is designed to be specifically recognized by a miRNA present in cells where transgene expression is undesirable and / or where a reduction in the level of transgene expression is desired. In certain embodiments, the miRNA target sequence is located at the 3'UTR, 5'UTR, and / or both the 3'UTR and 5'UTR. In some embodiments, the miRNA target sequence is operably ligated to a regulatory sequence of the expression cassette. In certain embodiments, the expression cassette includes at least two tandem repeats of a DRG-specific miRNA target sequence, where the at least two tandem repeats include at least a first miRNA target sequence and at least a second miRNA target sequence that may be the same as or different from the first. In certain embodiments, the tandem miRNA target sequences are contiguous or separated by 1 to 10 nucleic acid spacers, the spacers being not miRNA target sequences.
[0038] In certain embodiments, the vector genome or expression cassette contains at least one miRNA target sequence which is a miR-183 (or miRNA183) target sequence. In certain embodiments, the vector genome or expression cassette The vector genome or expression cassette contains a miR-183 target sequence including TIFF2023551911000001.tif9136 (SEQ ID NO: 11), and sequences complementary to the miR-183 seed sequence are underlined. In certain embodiments, the vector genome or expression cassette contains two or more copies (e.g., two or three copies) of a sequence that is 100% complementary to the miR-183 seed sequence. In certain embodiments, the miR-183 target sequence is about 7 to about 28 nucleotides long, and the miR-183 seed sequence The miR-183 target sequence includes at least one region that is at least 100% complementary to the seed sequence. In certain embodiments, the miR-183 target sequence contains a sequence that is partially complementary to sequence number 11 and therefore has one or more mismatches when aligned with sequence number 11. In certain embodiments, the miR-183 target sequence includes sequences that have at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches when aligned with sequence number 11, and the mismatches may be discontinuous. In certain embodiments, the miR-183 target sequence includes a 100% complementary region, which also constitutes at least 30% of the length of the miR-183 target sequence. In certain embodiments, the 100% complementary region includes a sequence that is 100% complementary to the miR-183 seed sequence. In certain embodiments, the remainder of the miR-183 target sequence has at least about 80% to about 99% complementarity with miR-183. In certain embodiments, the expression cassette or vector genome includes a miR-183 target sequence comprising a cleaved SEQ ID NO: 11, i.e., a sequence lacking at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at either or both of the 5' or 3' ends of SEQ ID NO: 11. In certain embodiments, the expression cassette or vector genome includes the transgene and one miR-183 target sequence. In yet another embodiment, the expression cassette or vector genome includes at least two, three, or four miR-183 target sequences.
[0039] In certain embodiments, the vector genome or expression cassette contains at least one miRNA target sequence which is a miR-182 target sequence. In certain embodiments, the vector genome or expression cassette contains a miR-182 target sequence comprising AGTGTGAGTTCTACCATTGCCAAA (SEQ ID NO: 20). In certain embodiments, the vector genome or expression cassette contains two or more copies (e.g., two or three copies) of a sequence that is 100% complementary to the miR-182 seed sequence. In certain embodiments, the miR-182 target sequence is about 7 to about 28 nucleotides long and contains at least one region that is at least 100% complementary to the miR-182 seed sequence. In certain embodiments, the miR-182 target sequence contains a sequence that is partially complementary to SEQ ID NO: 20 and therefore has one or more mismatches when aligned with SEQ ID NO: 20. In certain embodiments, the miR-183 target sequence, when aligned to sequence number 20, includes sequences having at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches, the mismatches may be discontinuous. In certain embodiments, the miR-182 target sequence includes a 100% complementary region, which also constitutes at least 30% of the length of the miR-182 target sequence. In certain embodiments, the 100% complementary region includes sequences that have 100% complementarity with the miR-182 seed sequence. In certain embodiments, the remainder of the miR-182 target sequence has at least about 80% to about 99% complementarity with miR-182. In certain embodiments, the expression cassette or vector genome includes a miR-182 target sequence containing a cleaved SEQ ID NO: 20 (i.e., a sequence lacking at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides at either the 5' or 3' end of SEQ ID NO: 20, or both). In certain embodiments, the expression cassette or vector genome includes the transgene and one miR-182 target sequence. In yet another embodiment, the expression cassette or vector genome includes at least two, three, or four miR-182 target sequences.
[0040] The term “tandem repeat” is used herein to refer to the presence of two or more consecutive miRNA target sequences. These miRNA target sequences may be consecutive, i.e., one 3' end may be directly after the other, either immediately upstream of the 5' end of the next sequence without an intervening sequence, or vice versa. In another embodiment, two or more of the miRNA target sequences are separated by a short spacer sequence. As used herein, “spacer” is any choice of, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length, located between two or more consecutive miRNA target sequences. This is a nucleic acid sequence. In certain embodiments, the spacer is a number of 1-8 nucleotides, 2-7 nucleotides, 3-6 nucleotides, 4 nucleotides, 4-9 nucleotides, 3-7 nucleotides, or longer. Preferably, the spacer is a non-coding sequence. In certain embodiments, the spacer may be four (4) nucleotides. In certain embodiments, the spacer is GGAT. In certain embodiments, the spacer is six (6) nucleotides. In certain embodiments, the spacer is CACGTG or GCATGC.
[0041] In certain embodiments, a tandem repeat may contain two, three, four or more identical miRNA target sequences. In certain embodiments, a tandem repeat may include at least two different miRNA target sequences, at least three different miRNA target sequences, or at least four different miRNA target sequences. In certain embodiments, a tandem repeat may contain two or three identical miRNA target sequences and a different fourth miRNA target sequence. In certain embodiments, an expression cassette may contain at least two different sets of tandem repeats. For example, the 3'UTR may contain a tandem repeat immediately downstream of the transgene, a UTR sequence, and two or more tandem repeats adjacent to the 3' end of the UTR. In another example, the 5'UTR may contain one or two or more miRNA target sequences. In yet another example, the 3' may contain a tandem repeat, and the 5'UTR may contain at least one miRNA target sequence. In certain embodiments, the expression cassette contains two, three, four or more tandem repeats that begin within approximately 0 to 20 nucleotides of the stop codon of the transgene. In other embodiments, the expression cassette contains miRNA tandem repeats at least 100 to approximately 4000 nucleotides from the stop codon of the transgene.
[0042] See also PCT / US19 / 67872, filed on December 20, 2019, currently published as WO2020 / 132455, claiming priority to U.S. Provisional Patent Application No. 62 / 783,956, filed on December 21, 2018, which is incorporated herein by reference. See also U.S. Patent Application No. 63 / 023,593 filed on 12 May 2020, U.S. Patent Application No. 63 / 038,488 filed on 12 June 2020, U.S. Patent Application No. 63 / 043,562 filed on 24 June 2020, U.S. Patent Application No. 63 / 079,299 filed on 16 September 2020, and U.S. Provisional Patent Application No. 63 / 152,042 filed on 22 February 2021, and International Patent Application No. PCT / US21 / 32003, all of which are incorporated herein by reference.
[0043] Optionally, the expression cassette may include a UBE3A coding sequence encoding the UBE3A protein, which is a fusion protein comprising the signal peptide and / or incorporation peptide described herein. In certain embodiments, the signal peptide and / or incorporation peptide is located at either the 5' or 3' position of the UBE3A coding sequence.
[0044] Vector genomes containing manipulated hUBE3A-isoform 1 coding sequences, such as SEQ ID NO: 1 (hSyn.hUbe3a-1.GSco.4XmiRNA183.SV40 (containing the miR183 target sequence)) and SEQ ID NO: 3 (hSyn.hUbe3a-1.GSco.SV40 without miR), are provided herein.
[0045] Vector genomes containing manipulated hUBE3A-isoform 2 coding sequences, such as SEQ ID NO: 5 (hSyn.hUbe3a-2.GSco.4XmiRNA183.SV40 (containing the miR183 target sequence)) and SEQ ID NO: 7 (hSyn.hUbe3a-2.GSco.SV40 without miR), are shown herein.
[0046] The composition in the expression cassette described herein is the composition described herein. Please understand that this is intended to apply to objects and methods.
[0047] vector In certain embodiments, the expression cassette encoding UBE3A is delivered to a neuron by a vector or viral vector, many of which are known and available in the art. In one embodiment, a vector comprising the UBE3A-targeting gene described herein is provided. In one embodiment, a vector comprising the expression cassette described herein is provided. In one embodiment, the vector is a non-viral vector. In a further embodiment, the non-viral vector is a plasmid. In another embodiment, the vector is a viral vector. Viral vectors include, but are not limited to, any virus suitable for gene therapy, including bocavirus, adenovirus, adeno-associated virus (AAV), herpesvirus, lentivirus, retrovirus, or parvovirus. However, for ease of understanding, adeno-associated virus is referred to herein as an exemplary viral vector. Thus, in one embodiment, an adeno-associated virus vector is provided, comprising a nucleic acid sequence and one or more elements of an expression cassette operably linked thereto to a regulatory element therefor.
[0048] As used herein, “vector” is a biological or chemical portion comprising a nucleic acid sequence that can be introduced into a suitable target cell for replication or expression of the nucleic acid sequence. Examples of vectors include, but are not limited to, recombinant viruses, plasmids, lipoplexes, polymerosomes, polyplexes, dendrimers, cell-permeable peptide (CPP) conjugates, magnetic particles, or nanoparticles. In one embodiment, the vector is a nucleic acid molecule having an exogenous or heterologous engineered nucleic acid encoding a functional gene product, which can then be introduced into a suitable target cell. Such a vector preferably has one or more origins of replication and one or more sites into which recombinant DNA can be inserted. For example, a vector encoding a drug resistance gene often has means for selecting cells containing the vector from cells that do not contain it. Common vectors include plasmids, viral genomes, and “artificial chromosomes.” Conventional methods for generating, producing, characterizing, or quantifying vectors are available to those skilled in the art.
[0049] As used herein, a recombinant viral vector is any suitable viral vector that targets a desired cell. Therefore, the recombinant viral vectors described herein preferably target one or more cells and tissues affected by Angelman syndrome, including cells of the central nervous system (e.g., the brain). The examples provide exemplary recombinant adeno-associated virus (rAAV). However, other suitable viral vectors may include, for example, recombinant adenovirus, recombinant parvovirus such as recombinant bocavirus, hybrid AAV / bocavirus, recombinant herpes simplex virus, recombinant retrovirus, or recombinant lentivirus. In preferred embodiments, these recombinant viruses are replication defects.
[0050] A "replication-deficient" virus or viral vector refers to a synthetic or artificial viral particle in which an expression cassette containing the gene of interest is packaged within a viral capsid or envelope, and any viral genome sequence packaged within the viral capsid or envelope is also replication-deficient; that is, it cannot produce progeny virions but retains the ability to infect target cells. In one embodiment, the genome of the viral vector does not contain genes encoding enzymes required for replication (the genome may be "gutless," containing only the gene of interest adjacent to signals required for amplification and packaging of the artificial genome), but these genes can be supplied during production. Therefore, replication and infection by progeny virions cannot occur without the presence of viral enzymes required for replication, thus in gene therapy. It is considered safe for use. Such replication-deficient viruses may be adeno-associated viruses (AAV), adenoviruses, lentiviruses (integrated or unintegrated), or other suitable sources of viruses.
[0051] "Plasmid" or "plasmid vector" is generally indicated herein by a lowercase 'p' before and / or after the vector name. Plasmids, other cloning and expression vectors that can be used in accordance with the present invention, their properties, and methods for constructing / manipulating them are readily apparent to those skilled in the art. In one embodiment, elements of the vector genome or expression cassette described herein, upon which a sequence to be supported is introduced, are manipulated into a suitable genetic element (vector) useful for generating a viral vector and / or for delivery to host cells, such as naked DNA, phages, transposons, cosmids, episomes, etc. The selected vector may be delivered by any suitable method, including transfection, electroporation, liposome delivery, membrane fusion techniques, fast DNA-coated pellets, viral infection, and protoplast fusion. Methods used to construct such constructs are known to those skilled in the art in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. For example, Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring See Harbor, NY.
[0052] The terms “transgene” or “target gene” as used interchangeably herein mean a nucleic acid sequence encoding an exogenous and / or engineered protein under the control of a promoter and / or other regulatory elements in an expression cassette, rAAV genome, recombinant plasmid, or production plasmid, vector, or host cell as described herein.
[0053] When used to describe nucleic acid sequences or proteins, the term “heterogeneous” means that the nucleic acid or protein originates from a different organism or a different species of the same organism from the host cell or target in which it is expressed. When used in relation to proteins or nucleic acids in plasmids, expression cassettes, or vectors, the term “heterogeneous” means that the protein or nucleic acid exists in a different sequence or subsequence that is not found in nature in the same relationship to one another.
[0054] As used herein, the term “host cell” may refer to a packaging cell line from which a vector (e.g., recombinant AAV) is produced from a production plasmid. Alternatively, the term “host cell” may refer to any target cell in which the expression of the gene product described herein is desired. Thus, “host cell” refers to a prokaryotic or eukaryotic cell (e.g., a human cell or an insect cell) containing exogenous or heterologous DNA introduced into the cell by any means, e.g., electroporation, calcium phosphate precipitation, microinjection, transformation, viral infection, transfection, liposome delivery, membrane fusion techniques, fast DNA-coated pellets, viral infection, and protoplast fusion. In certain embodiments herein, the term “host cell” refers to a culture of cells of various mammalian species for in vitro evaluation of the compositions described herein. In other embodiments herein, the term “host cell” refers to a cell used to generate and package a viral vector or recombinant virus. In further embodiments, the term “host cell” is a neuron, e.g., a neuron of the CNS.
[0055] As used herein, the term “target cell” refers to any target cell in which the expression of a heterologous nucleic acid sequence or protein is desired. In certain embodiments, the target cell is a neuron of the CNS, in particular a neuron having a mutated or deficient maternal UBE3A allele, or a neuron lacking UBE3A expression.
[0056] As used herein, “vector genome” refers to a nucleic acid sequence packaged inside a parvovirus (e.g., rAAV) capsid that forms a viral particle. Such a nucleic acid sequence contains an AAV inverted terminal repeat (ITR). In the examples herein, the vector genome contains at least an AAV5'ITR, a coding sequence, and an AAV3'ITR, from 5' to 3'. ITRs other than those from AAV2, AAV from a different source than the capsid, or full-length ITRs may be selected. In certain embodiments, the ITR is from the same AAV source as the AAV that provides rep function or trans-complementary AAV during production. Furthermore, other ITRs, such as self-complementary (scAAV) ITRs, may be used. In addition, the vector genome contains regulatory sequences that direct the expression of the gene product. Preferred components of the vector genome are discussed in more detail herein. For example, a "vector genome" contains, at a minimum, a vector-specific sequence and a nucleic acid sequence encoding UBE3A (manipulatedly linked from 5' to 3' to a regulatory sequence that directs its expression in a target sequence), where the vector-specific sequence may be a terminal repeat sequence that specifically packages the vector genome to a viral vector capsid or envelope protein. For example, the AAV inverted terminal repeat is used for packaging AAV and certain other parvovirus capsids. The lentiviral long terminal repeat may be used when packing into a lentiviral vector is desired. Similarly, other terminal repeats (e.g., retroviral long terminal repeats) may be selected.
[0057] Examples of vector genomes encoding UBE3A isoform 1 provided herein include SEQ ID NO: 1 (AAV2-5'ITR-hSyn.hUbe3a-1.GSco.4XmiRNA183.SV40-AAV2-3'ITR) and SEQ ID NO: 3 (AAV2-5'ITR-hSyn.hUbe3a-1.GSco.SV40-AAV2-3'ITR).
[0058] As used herein, the term “AAV” refers to naturally occurring adeno-associated viruses, adeno-associated viruses available to those skilled in the art and / or available in terms of the compositions and methods described herein, and artificial AAVs. Adeno-associated virus (AAV) viral vectors are AAV nuclease (e.g., DNase) resistant particles having an AAV protein capsid, in which an expression cassette is packaged, flanked by the inverted terminal repeat (ITR) of AAV for delivery to target cells. Nuclease-resistant recombinant AAV (rAAV) indicates that the AAV capsid is fully constructed, protecting these packaged vector genome sequences from degradation (digestion) during the nuclease incubation step, which is designed to remove any contaminating nucleic acids that may be present in the production process. In many cases, the rAAVs described herein are DNase resistant.
[0059] In the following embodiments, the adeno-associated virus of clade F is AAVhu68. See WO2018 / 160582, which is incorporated herein by reference in its entirety. In other embodiments, a different AAV capsid is selected from a different clade, e.g., from clades A, B, C, D, or E, or from an AAV source outside of any of these clades. For example, another preferred capsid is AAVrh91. See WO2020 / 223231 filed November 5, 2020, U.S. Patent Application No. 63 / 065,616 filed August 14, 2020, and U.S. Patent Application No. 63 / 109,734 filed November 4, 2020, and International Patent Application No. PCT / US21 / 55436, which are incorporated herein by reference. In certain embodiments, an AAV capsid with reduced capsid deamidation may be selected. For example, see PCT / US19 / 19804 and PCT / US18 / 19861, both filed on February 27, 2019, and incorporated herein by reference in their entirety. See also PCT / US20 / 030266 filed on April 29, 2020, WO2020 / 223231, which is currently published, and international application PCT / US21 / 45945 filed on August 13, 2021.
[0060] In other embodiments, the source of the AAV capsid may be one of several dozen naturally occurring and available adeno-associated viruses, as well as engineered or artificial AAVs. The AAV capsid consists of 60 capsid (cap) protein subunits, VP1, VP2, and VP3, arranged icosahedral symmetrically in a ratio of approximately 1:1:10 to 1:1:20, depending on the selected AAV. Various AAVs can be selected as the source of the capsid for the AAV viral vector described above. See, for example, U.S. Patent Application Publication 2007 / 0036760-A1, U.S. Patent Application Publication 2009 / 0197338-A1, and EP1310571. See also WO2003 / 042397 (AAV7 and other monkey AAVs), U.S. Patents 7790449 and 7282199 (AAV8), WO2005 / 033321 and U.S. 7,906,111 (AAV9), and WO2006 / 110689 and WO2003 / 042397 (AAVrh10). These documents also describe and are incorporated by reference other AAVs that may be selected to generate AAVs. Of the well-characterized AAVs isolated or manipulated from humans or non-human primates (NHPs), human AAV2 was the first AAV developed as a gene transfer vector and is widely used in efficient gene transfer experiments in various target tissues and animal models. Unless otherwise specified, the AAV capsids, ITRs, and other selected AAV components described herein may be readily selected from any AAV, including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV8bp, AAV7M8, and AAVAnc80. See, for example, WO2005 / 033321, incorporated herein by reference. In one embodiment, the AAV capsid is the AAV9 capsid or a variant thereof. In certain embodiments, the capsid protein is designated by a number or a combination of a number and letters following the term "AAV" in the name of the rAAV vector.See also PCT / US19 / 19804 and PCT / US19 / 19861, filed on February 27, 2019, respectively, titled “Novel Adeno-Associated Virus (AAV) Vectors, AAV Vectors Having Reduced Capsid Deamidation And Uses Therefor,” which are incorporated herein by reference in their entirety.
[0061] ITR or other AAV components can be readily isolated or manipulated from AAV using techniques available to those skilled in the art. Such AAV can be isolated, manipulated, or obtained from academic, commercial, or public sources (e.g., American Type Culture Collection, Manassas, VA). Alternatively, AAV sequences can be manipulated through synthesis or other suitable means by referencing publicly available sequences, such as those available in the literature or databases such as GenBank or PubMed. AAV viruses can be manipulated by conventional molecular biological techniques, allowing these particles to be optimized for cell-specific delivery of nucleic acid sequences, minimizing immunogenicity, adjusting stability and particle lifetime, efficient degradation, and precise delivery to the nucleus, among other things.
[0062] As used herein, the terms “rAAV” and “recombinant AAV vector” are interchangeable and not limited to, but mean an AAV comprising a capsid protein and a vector genome packaged therein, wherein the vector genome contains nucleic acids different from those of the AAV. Examples of rAAV include “pseudo-rAAV,” where a viral vector packages one AAV into the capsid of a different AAV capsid protein (e.g., The vector genome contains an inverted terminal repeat of AAV2. In one embodiment, the capsid protein is a non-naturally occurring capsid. Such an artificial capsid can be produced by any preferred technique using a selected AAV sequence (e.g., a fragment of the vp1 capsid protein) in combination with a heterologous sequence that can be obtained from a different selected AAV which is a non-adjacent portion of the same AAV, from a non-AAV viral source, or from a non-viral source. The selected genetic elements can be delivered by any preferred method, including transfection, electroporation, liposome delivery, membrane fusion techniques, fast DNA coated pellets, viral infection, and protoplast fusion. The methods used to construct such constructs are known to those skilled in the art of nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY (2012).
[0063] As used herein, when used to refer to vp capsid proteins, the term “heterogeneous” or any grammatical variation thereof refers to a group of non-identical elements having, for example, vp1, vp2, or vp3 monomers (proteins) with different modified amino acid sequences. Sequence ID No. 15 provides the encoded amino acid sequence of the AAVhu68 vp1 protein. The term “heterogeneous” as used in relation to vp1, vp2, and vp3 proteins (alternatively referred to as isoforms) refers to the differences in the amino acid sequences of the vp1, vp2, and vp3 proteins within the capsid. The AAV capsid contains subpopulations within the vp1, vp2, and vp3 proteins that have the predicted amino acid residue modifications. These subpopulations contain, at a minimum, certain deamidated asparagine (N or Asn) residues. For example, a particular subpopulation contains at least one, two, three, or four highly deamidated asparagine(N) positions in the asparagine-glycine pair, and optionally further contains other deamidated amino acids, where deamidation results in amino acid changes and other optional modifications.
[0064] As used herein, a “subpopulation” of vp proteins means, unless otherwise specified, a group of vp proteins that share at least one defined common feature and consist of at least one group member and fewer members than all members of the reference group. For example, a “subpopulation” of vp1 proteins is, unless otherwise specified, at least one vp1 protein and fewer than all vp1 proteins in an assembled AAV capsid. A “subpopulation” of vp3 proteins is, unless otherwise specified, one vp3 protein and fewer than all vp3 proteins in an assembled AAV capsid. For example, in an assembled AAV capsid, vp1 proteins may be a subpopulation of vp proteins, vp2 proteins may be another subpopulation of vp proteins, and vp3 may be yet another subpopulation of vp proteins. In another example, the vp1, vp2, and vp3 proteins may contain subpopulations having different modifications in, for example, at least one, two, three, or four highly deamidated asparagines, such as asparagine-glycine pairs.
[0065] In one embodiment, the AAV vector provided herein comprises an AAV capsid and an expression cassette, wherein the expression cassette comprises a nucleic acid sequence encoding one or more elements of the UBE3A gene and a regulatory element that directs the expression of the elements of the UBE3A gene in a host cell. The AAV vector also comprises an AAV ITR sequence.
[0066] The ITR is a genetic element responsible for genome replication and packaging during vector production and is the only viral cis element required to generate rAAV. In one embodiment, the ITR is derived from a different AAV than the one supplying the capsid. Preferred implementation In this case, an ITR sequence derived from AAV2, or a deleted version thereof (ΔITR), may be used for convenience and to facilitate regulatory approval. However, ITRs derived from other AAV sources may be selected. If the ITR source is AAV2 and the AAV capsid is from another AAV source, the resulting vector may be referred to as a pseudotype. Typically, an AAV vector genome includes an AAV5'ITR, a nucleic acid sequence encoding the gene product, an optional regulatory sequence, and an AAV3'ITR. However, other configurations of these elements may also be preferred. In one embodiment, a self-complementary AAV is used. A shortened version of the 5'ITR, referred to as ΔITR, is described, in which the D sequence and terminal separation sites (trs) are deleted. In a particular embodiment, the vector genome includes a 130-base pair shortened AAV2 ITR, in which the outer "a" element is deleted. The shortened ITR is restored to its 145 base pair wild-type length during vector DNA amplification using the internal A element as a template. In other embodiments, full-length AAV5' and 3' ITRs are used.
[0067] In one embodiment, the regulatory sequence is selected so that the total rAAV vector genome is approximately 2.0 to approximately 5.5 kilobases in size. In another embodiment, the regulatory sequence is selected so that the total rAAV vector genome is approximately 2.9 to approximately 5.5 kilobases in size. In yet another embodiment, the regulatory sequence is selected so that the total rAAV vector genome is approximately 2.9 kb in size. In yet another embodiment, it is desirable that the rAAV vector genome approximates the size of the natural AAV genome. Therefore, in yet another embodiment, the regulatory sequence is selected so that the total rAAV vector genome is approximately 4.7 kb in size. In yet another embodiment, the total rAAV vector genome is less than approximately 5.2 kb in size. The size of the vector genome may be manipulated based on the size of the regulatory sequence, including promoters, enhancers, introns, poly(A), etc. See Wu et al., Mol Ther, Jan 2010, 18(1):80-6, incorporated herein by reference.
[0068] In certain embodiments, provided herein is an rAAV useful as a CNS-targeted therapy for the treatment of subjects having Angelman syndrome (AS), wherein the rAAV comprises an AAV capsid and a vector genome packaged therein, the vector genome comprising (a) an AAV5' inverted terminal repeat (ITR), (b) a sequence encoding UBE3A operably linked to a regulatory element that directs expression in host cells, (c) an expression-directing regulatory element, and (d) an AAV3'ITR. In certain embodiments, provided herein is an rAAV useful as a CNS-targeted therapy for the treatment of subjects having Angelman syndrome (AS), wherein the rAAV comprises an AAV capsid and a vector genome packaged therein, the vector genome comprising (a) an AAV5' inverted terminal repeat (ITR), (b) a sequence encoding UBE3A operably linked to a regulatory element that directs expression in host cells, (c) one / more peptides (e.g., a signal peptide and / or uptake peptide) optionally, (d) a regulatory element that directs expression, and (e) an AAV3'ITR. In one embodiment, the rAAV is tropism to CNS cells (e.g., an rAAV carrying an AAVhu68 capsid or an AAVrh91 capsid) and / or contains a neuron-specific expression regulatory element (e.g., a synapsin promoter). In one embodiment, a construct is provided which is a vector (e.g., a plasmid) useful for generating viral vectors. In one embodiment, AAV5'ITR is AAV2 ITR, and AAV3'ITR is AAV2 ITR. In one embodiment, rAAV comprises the AAV capsid described herein. In one embodiment, rAAV comprises AAVhu68 capsid. In other embodiments, rAAV comprises AAVrh91 capsid. Sequence ID No. 18 provides the encoded amino acid sequence of the AAVrh91 vp1 protein.
[0069] The recombinant adeno-associated viruses (AAVs) described herein are produced using known techniques It can be generated. See, for example, WO2003 / 042397, WO2005 / 033321, WO2006 / 110689, and US7588772B2. Such a method involves culturing a host cell containing a nucleic acid sequence encoding an AAV capsid, a functional rep gene, an expression cassette described herein adjacent to an AAV inverted terminal repeat (ITR), and a suitable helper that functions to enable packaging the expression cassette into an AAV capsid protein. Also provided herein is a host cell containing a nucleic acid sequence encoding an AAV capsid, a functional rep gene, a vector genome described herein, and a suitable helper that functions to enable packaging the expression cassette into an AAV capsid protein. In one embodiment, the host cell is a HEK293 cell. These methods are described in more detail in WO2017 / 160360A2, which is incorporated herein by reference.
[0070] Other methods for producing rAAV available to those skilled in the art may be used. Preferred methods, but are not limited to, production via a baculovirus expression system or yeast. For example, see Robert M. Kotin, Large-scale recombinant adeno-associated virus production. Hum Mol Genet. 2011 Apr 15;20(R1):R2-R6. Published online 2011 Apr 29. doi:10.1093 / hmg / ddr141, and Aucoin MG et al., Production of adeno-associated viral vectors in insect cells using triple infection: optimization. of baculovirus concentration ratios.Biotechnol Bioeng.2006 Dec 20;95(6):1081-92, SAMI S.THAKUR,Production of Recombinant Adeno-associated viral vectors in yeast.Thesis presented to the Graduate School of the University of Florida,2012、Kondratov O et al.Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells,Mol Ther.2017 Aug 10.pii:S1525-0016(17)30362-3.doi:10.1016 / j.ymthe.2017.08.003.[Epub ahead of print]、Mietzsch M et al,OneBac 2.0:Sf9 Cell Lines for Production of AAV1,AAV2,and AAV8 Vectors with Minimal Encapsidation of Foreign DNA.Hum Gene Ther Methods.2017 Feb;28(1):15-22.doi:10.1089 / hgtb.2016.164.、Li L et al.Production and characterization of novel recombinant adeno-associated virus replicative-form genomes:a eukaryotic source of DNA for gene transfer.PLoS One.2013 Aug 1;8(8):e69879.doi:10.1371 / journal.pone.0069879 J Invertebr Pathol.2011 Jul;107 Suppl:S80-93.doi:10.1016 / j.jip.2011.05.008 and Kotin RM,Larg e-scale recombinant adeno-associated virus production.Hum Mol Genet.2011 Apr 15;20(R1):R2-6.doi:10.1093 / hmg / ddr141.Epub 2011 Apr 29
[0071] Purification of the vector drug product and removal of empty capsids is performed by two-step affinity chromatography at high salt concentrations, followed by anion exchange resin chromatography. These methods are detailed in WO2017 / 160360, entitled “Scalable Purification Method for AAV9,” and WO2017 / 100674, entitled “Scalable Purification Method for AAV1,” which are incorporated herein by reference. Briefly, a method for separating rAAV particles having a packaged genomic sequence from a genomically deficient AAV intermediate comprises subjecting a suspension containing recombinant AAV9 or AAV virus particles and AAV capsid intermediates to high-performance liquid chromatography, wherein the AAV9 virus particles and AAV intermediates are bound to a strongly anion exchange resin equilibrated at pH approximately 10.2 for rAAV9 or approximately 9.8 for AAV1, and subjected to a salt gradient while monitoring the eluate with ultraviolet absorbance at approximately 260 and approximately 280. In this method, the complete AAV capsid is recovered from the fraction that elutes when the A260 / A280 ratio reaches the infection point. In one example, the affinity chromatography step may involve applying the diafiltration product to an AAV-specific resin that efficiently captures the selected AAV serotype. Under these ionic conditions, a significant percentage of residual cellular DNA and proteins flow through the column, and the AAV particles are efficiently captured.
[0072] Conventional methods for characterizing or quantifying rAAV are available to those skilled in the art. To calculate the content of empty and packed particles, the VP3 band volume for a selected sample (e.g., in the examples herein, a preparation purified with an iodixanol gradient, where GC = number of particles) is plotted against the loaded GC particles. The number of particles in the band volume of the test article peak is calculated using the resulting linear equation (y = mx + c). The number of particles per 20 μL loaded (pt) is then multiplied by 50 to obtain particles (pt) / mL. Pt / mL is divided by GC / mL to obtain the ratio of particles to genome copies (pt / GC). Pt / mL ~ GC / mL gives empty pt / mL. The percentage of empty particles is obtained by dividing empty pt / mL by pt / mL and multiplying by 100. In general, methods for assaying AAV vector particles containing empty capsids and packaged genomes are known in the art. For example, Grimm et al., Gene Therapy (1999) 6:1322-1330, Sommer et al. See al., Molec. Ther. (2003) 7:122-128. To test for denatured capsids, the method comprises subjecting a treated AAV stock to SDS-polyacrylamide gel electrophoresis (e.g., a gradient gel containing 3-8% tris acetate in buffer) of any gel capable of separating three capsid proteins, then trialing the gel until the sample material is separated, and blotting the gel on a nylon or nitrocellulose membrane, preferably nylon. Then, an anti-AAV capsid antibody is used as the primary antibody to bind to the denatured capsid protein, preferably an anti-AAV capsid monoclonal antibody, most preferably a B1 anti-AAV-2 monoclonal antibody (Wobus et al., J. Viral. (2000) 74:9281-9293). Next, a secondary antibody is used, which includes means for detecting binding to the primary antibody and to an anti-IgG antibody containing a detection molecule covalently bound to the primary antibody, more preferably to the antibody, and most preferably to a sheep anti-mouse IgG antibody covalently bound to horseradish peroxidase. To semi-quantitatively determine the binding between the primary antibody and the secondary antibody, a method for detecting the binding is used, preferably a detection method capable of detecting radioactive isotope radiation, electromagnetic radiation, or a colorimetric change, most preferably chemiluminescence detection. A kit is used. For example, in SDS-PAGE, a sample can be taken from the column fraction and heated in SDS-PAGE packing buffer containing a reducing agent (e.g., DTT), and the capsid protein was degraded in a precast gradient polyacrylamide gel (e.g., Novex). Silver staining can be performed using SilverXpress (Invitrogen, CA) according to the manufacturer's instructions, or using other suitable staining methods, namely SYPRO ruby or Coomassie staining. In one embodiment, the concentration of the AAV vector genome (vg) in the column fraction can be measured by quantitative real-time PCR (Q-PCR). The sample is diluted and digested with DNase I (or another suitable nuclease) to remove exogenous DNA. After nuclease inactivation, the sample is further diluted and amplified using a TaqMan® fluorescence generating probe specific to the DNA sequence between primers and primers. The number of cycles required to reach a specified level of fluorescence (threshold cycle, Ct) is measured for each sample on an Applied Biosystems Prism 7700 sequence detection system. A standard curve for the Q-PCR reaction is generated using plasmid DNA containing the same sequence as that contained in the AAV vector. The vector genome titer is determined by normalizing the cycle threshold (Ct) value obtained from the sample against the Ct value of the plasmid standard curve. Digital PCR-based endpoint assays are also available.
[0073] In one embodiment, an optimized q-PCR method utilizing a broad-spectrum serum proteinase, such as proteinase K (e.g., available from Qiagen), is used. More specifically, the optimized qPCR genomic titer assay is similar to the standard assay, except that after DNase I digestion, the sample is diluted with proteinase K buffer, treated with proteinase K, and subsequently thermally inactivated. Preferably, the sample is diluted with an amount of proteinase K buffer equal to the sample size. The proteinase K buffer can be concentrated more than 2-fold. Typically, the proteinase K treatment is about 0.2 mg / mL, but can vary from 0.1 mg / mL to about 1 mg / mL. The treatment step is generally carried out at about 55°C for about 15 minutes, but can be carried out at a lower temperature (e.g., about 37°C to about 50°C) for a longer time (e.g., about 20 minutes to about 30 minutes), or at a higher temperature (e.g., up to about 60°C) for a shorter time (e.g., about 5 to 10 minutes). Similarly, thermal inactivation is generally about 15 minutes at about 95°C, but the temperature can be lowered (e.g., about 70 to about 90°C), and the time can be extended (e.g., about 20 to about 30 minutes). The sample is then diluted (e.g., 1000-fold) and subjected to TaqMan analysis as described in standard assays.
[0074] In addition, or alternatively, droplet digital PCR (ddPCR) may be used. For example, a method for determining single-stranded and self-complementary AAV vector genome titers by ddPCR is described. See, for example, M. Lock et al, Hu Gene Therapy Methods, Hu Gene Ther Methods. 2014 Apr;25(2):115-25. doi:10.1089 / hgtb.2013.131.Epub 2014 Feb 14.
[0075] Methods are also available for determining the ratios between the capsid proteins vp1, vp2, and vp3. For example, Vamseedhar Rayaprolu et al., Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics, J Virol. 2013 Dec;87(24):13150-13160, Buller RM, Rose JA. 1978. Characterization of adenovirus-associated virus-induced polypeptides in KB cells. J. Virol. 25:331-338, and Rose JA, Maizel JV, Inman JK, Shatkin AJ.1971.S See tructural proteins of adenovirus-associated viruses. J.Virol.8:766-770.
[0076] It should be understood that the compositions in the vectors described herein are intended to be applied to other compositions and methods described herein.
[0077] composition Provided is an aqueous suspension suitable for administration to subjects requiring treatment of AS, wherein the suspension comprises an aqueous suspension and a vector comprising an engineered nucleic acid sequence encoding the UBE3A gene, which is operably linked to a regulatory element described herein. In one embodiment, a therapeutically effective amount of the vector is contained in the suspension.
[0078] nucleic acid In certain embodiments, the pharmaceutical composition comprises an expression cassette comprising a nucleic acid encoding UBE3A isoform 1 and a nonviral delivery system. Examples of such systems include, for example, naked DNA, naked RNA, inorganic particles, lipids or lipid-like particles, chitosan-based formulations, and others known in the art (for example, described by Ramamoorth and Narvekar, cited above). In other embodiments, the pharmaceutical composition is a suspension comprising an expression cassette containing the UBE3A gene in a viral vector system. In certain embodiments, the pharmaceutical composition comprises a non-replicating viral vector. Suitable viral vectors may include any suitable delivery vector, such as, for example, recombinant adenovirus, recombinant lentivirus, recombinant bocavirus, recombinant adeno-associated virus (AAV), or another recombinant parvovirus. In certain embodiments, the viral vector is a recombinant AAV for delivering UBE3A isoform 1 to a patient requiring such delivery. In certain embodiments, the viral vector is a recombinant AAV for delivering UBE3a isoform 3 to a patient requiring such delivery.
[0079] In one embodiment, the composition comprises a final formulation suitable for delivery to a subject, for example, an aqueous liquid suspension buffered to a physiologically suitable pH and salt concentration. Optionally, one or more surfactants are present in the formulation. In another embodiment, the composition may be transported as a concentrate that is diluted for administration to a subject. In yet another embodiment, the composition may be lyophilized and reconstituted at the time of administration.
[0080] In one embodiment, the suspension further comprises a surfactant, preservative, excipient, and / or buffer dissolved in an aqueous suspension. In one embodiment, the buffer is PBS. A variety of suitable solutions are known, including one or more of the following: buffered saline, a surfactant, a physiologically suitable salt or mixture of salts adjusted to an ionic strength equivalent to about 100 mM sodium chloride (NaCl) to about 250 mM sodium chloride, or a physiologically suitable salt adjusted to an equivalent ionic concentration. Suitable surfactants, or combinations of surfactants, are from among poloxamers, i.e., nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) adjacent to two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)), such as SOLUTOL HS. The following can be selected: 15 (macrogol-15 hydroxystearate), LABRASOL (polyoxycaprylic acid glyceride), polyoxy-10 oleyl ether, TWEEN (polyoxyethylene sorbitan fatty acid ester), ethanol, and polyethylene glycol. In one embodiment, the formulation contains poloxamer. The pH may be in the range of 6.5 to 8.5, or 7 to 8.5, or 7.5 to 8. Since the pH of cerebrospinal fluid is approximately 7.28 to approximately 7.32, a pH within this range may be desirable for intrathecal delivery, while a pH of 6.8 to approximately 7.2 may be desirable for intravenous delivery. However, However, for other delivery routes, other pH ranges within the broadest range, as well as sub-ranges of these, may be selected.
[0081] Also provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a vector containing a nucleic acid sequence encoding one or more components of UBE3A operably linked to a regulatory element described herein. As used herein, “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antimicrobial and antifungal agents, isotonic and absorption retardants, buffers, carrier solutions, suspensions, colloids, etc. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active ingredients may also be incorporated into the composition. The term “pharmaceutically acceptable” means molecular entities and compositions that, when administered to a host, do not produce allergic or similar adverse reactions. To introduce the compositions of the present invention into suitable host cells, delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, and vesicles may be used. In particular, rAAV vectors delivering the UBE3A transgene may be formulated for delivery encapsulated in any of the following: lipid particles, liposomes, vesicles, nanospheres, or nanoparticles. In one embodiment, a therapeutically effective amount of the vector is included in the pharmaceutical composition. A suitable carrier can be readily selected by those skilled in the art, taking into account the indication to which the vector is directed. For example, one suitable carrier is saline, which can be formulated with various buffer solutions (e.g., phosphate-buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The choice of carrier is not limiting to the present invention. Other conventional pharmaceutically acceptable carriers, such as preservatives or chemical stabilizers. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. Suitable chemical stabilizers include gelatin and albumin.
[0082] The term "pharmaceutically acceptable" refers to molecular entities and compositions that, when administered to a host, do not cause allergic or similar adverse reactions.
[0083] As used herein, the terms “dosage” or “amount” may refer to the total amount or total quantity delivered to a subject in the course of treatment, or the amount or quantity delivered in a single unit (or multiple units or divided doses).
[0084] The aqueous suspension or pharmaceutical composition described herein is designed to be delivered to a subject requiring it by any preferred route or combination of different routes. In one embodiment, the pharmaceutical composition comprises an expression cassette or vector described herein and a formulation buffer suitable for delivery via an intraventricular (ICV), intrathecal (IT), intracisional, or intravenous (IV) administration route. Alternatively, other administration routes (e.g., oral, inhalation, intranasal, intratracheal, intra-arterial, intraocular, intramuscular, and other parenteral routes) may be selected.
[0085] As used herein, the terms “intrathecal delivery” or “intrathecal administration” refer to the route of drug administration via injection into the subarachnoid space to reach the spinal canal, more specifically, the cerebrospinal fluid (CSF). Intrathecal delivery may include lumbar puncture, intraventricular, lateral ventricle (icv), suboccipital / cisternal, and / or C1-2 puncture. For example, material may be introduced via lumbar puncture to diffuse throughout the subarachnoid space. In another example, the injection may be into the cisterna magna (intracapsular manga; ICM). Intracapsular delivery may increase vector diffusion and / or reduce toxicity and inflammation caused by administration. For example, Christian Hinderer et al., Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna,Mol Ther Methods Clin Dev.2014;1:14051.Published See online Dec 10, 2014. doi:10.1038 / mtm.2014.51. As used herein, the terms "cisternal delivery" or "cisternal administration" refer to the direct route of drug administration into the cerebrospinal fluid of the ventricles or into the cisterna magna, more specifically, the route of drug administration via suboccipital puncture or via direct injection into the cisterna magna or via a permanently placed tube.
[0086] In one aspect, provided herein is a pharmaceutical composition comprising the vector described herein in a formulation buffer. In certain embodiments, the replication-deficient viral composition is formulated in dosage units to contain an amount of replication-deficient virus in the range of all integers or fractional amounts, and preferably 1.0×10 12 GC to 1.0×10 14 GC (for treating an average subject of 70 kg body weight) in the range of about 1.0×10 9 GC to about 1.0×10 16 GC. In one embodiment, the composition is formulated to contain at least 1×10 9 , 2×10 9 , 3×10 9 , 4×10 9 , 5×10 9 , 6×10 9 , 7×10 9 , 8×10 9 , or 9×10 9 GC per dose, including all integers or fractions within the range. In another embodiment, the composition is formulated to contain at least 1×10 10 , 2×10 10 , 3×10 10 , 4×10 10 , 5×10 10 , 6×10 10 , 7×10 10 >, 8×10 10 , or 9×10 10 GC per dose, including all integers or fractions within the range. In another embodiment, the composition is formulated to contain at least 1×10 11 , 2×10 11, 3 x 10 11 , 4×10 11 , 5×10 11 , 6×10 11 , 7×10 11 , 8×10 11 , or 9×10 11 The formulation is made to contain GC. In another embodiment, the composition contains all integers or decimals within the range, at least 1 × 10 per dose. 12 , 2×10 12 , 3 x 10 12 , 4×10 12 , 5×10 12 , 6×10 12 , 7×10 12 , 8×10 12 , or 9×10 12 The formulation is made to contain GC. In another embodiment, the composition contains all integers or decimals within the range, at least 1 × 10 per dose. 13 , 2×10 13 , 3 x 10 13 , 4×10 13 , 5×10 13 , 6×10 13 , 7×10 13 , 8×10 13 , or 9×10 13 The formulation is made to contain GC. In another embodiment, the composition contains all integers or decimals within the range, at least 1 × 10 per dose. 14 , 2×10 14 , 3 x 10 14 , 4×10 14 , 5×10 14 , 6×10 14 , 7×10 14 , 8×10 14 , or 9×10 14 The formulation is made to contain GC. In another embodiment, the composition contains all integers or decimals within the range, at least 1 × 10 per dose. 15 , 2×10 15 , 3 x 10 15 , 4×10 15 , 5×10 15 , 6×10 15 , 7×10 15 , 8×10 15 , or 9×1015 It is formulated to contain GC. In one embodiment, for human application, the dose is 1 × 10 per dose, including all integers or decimals within the range. 10 ~Approx. 1×10 12 It could be within the scope of garbage collection.
[0087] In one embodiment, a pharmaceutical composition is provided comprising rAAV as described herein in a formulation buffer. In one embodiment, rAAV is approximately 1 × 10⁻⁶ 9 Genome copies (GC) / mL ~ approximately 1 × 10⁶ 14 It is formulated at GC / mL. In a further embodiment, rAAV is approximately 3 × 10⁻¹⁶ 9 GC / mL ~ approx. 3×10 13 It is formulated at GC / mL. In further embodiments, rAAV is approximately 1 × 10⁻⁶ 9 GC / mL ~ approx. 1×10 13 It is formulated in GC / mL. In one embodiment, rAAV is at least about 1 × 10⁻¹⁶ 11 It is formulated using GC / mL.
[0088] The appropriate volume for delivering these doses and concentrations can be determined by those skilled in the art. For example, volumes of about 1 μL to 150 mL may be selected, with higher volumes being chosen for adults. Typically, for neonates, appropriate volumes may be about 0.5 mL to 10 mL, and for older infants, about 0.5 mL to 15 mL. For toddlers, about 0.5 mL Volumes of approximately 20 mL may be selected. For children, a maximum volume of approximately 30 mL may be selected. For early teens and teenagers, a maximum volume of approximately 50 mL may be selected. In yet another embodiment, the patient may receive intrathecal administration in a volume of approximately 5 mL to approximately 15 mL, or approximately 7.5 mL to approximately 10 mL. Other suitable volumes and dosages may be determined. The dosage is adjusted to balance the therapeutic benefit with any side effects, and such dosage may vary depending on the therapeutic use in which the recombinant vector is used.
[0089] In the case of an AAV viral vector, quantification of genomic copies ("GC") can be used as a measure of the dose contained in an aqueous suspension or pharmaceutical composition. The genomic copy (GC) number of the replication-deficient viral composition of the present invention can be determined using any method known in the art. One method for performing GC number titration of AAV is as follows. A purified AAV vector sample is first treated with DNase to eliminate non-capsidated AAV genomic DNA or contaminating plasmid DNA from the production process. The DNase-resistant particles are then heat-treated to release the genome from the capsid. The released genome is then quantified by real-time PCR or quantitative PCR using a primer / probe set that targets a specific region of the viral genome (usually the polyA signal). The replication-deficient viral composition can be formulated in dosage units containing an amount of replication-deficient virus in the range of about 1.0×10 9 GC to about 1.0×10 15 GC, preferably 1.0×10 12 GC to 1.0×10 14 GC. The replication-deficient viral composition in the formulation preferably has a concentration of about 1.0×10 9 GC, about 5.0×10 9 GC, about 1.0×10 10 GC, about 5.0×10 10 GC, about 1.0×10 11 GC, about 5.0×10 11 GC, about 1.0×10 12 GC, about 5.0×10 12 GC, about 1.0×10 13 GC, about 5.0×10 13 GC, about 1.0×10 14 GC, about 5.0×10 14 GC, or about 1.0×10 15It is GC. Alternative or additional methods for performing titration of the AAV GC count are, for example, the oqPCR or digital droplet PCR (ddPCR) method described by reference herein, M. Lock et al, Hum Gene Ther Methods. 2014 Apr;25(2):115-25.doi:10.1089 / hgtb.2013.131.Epub 2014 Feb 14.
[0090] It should be understood that the compositions in the pharmaceutical compositions described herein are intended to be applied to other compositions, regimens, embodiments, embodiments, and methods described herein.
[0091] method In certain embodiments, an expression cassette, nucleic acid, or virus or non-viral vector is used in the preparation of a pharmaceutical product. In certain embodiments, its use for treating Angelman syndrome is provided in subjects requiring treatment for Angelman syndrome.
[0092] As used herein, the terms “treatment” or “to treat” are defined to include administering one or more of the compounds or compositions described herein to a subject for the purpose of reducing one or more symptoms of UBE3A deficiency or Angelman syndrome (AS). Accordingly, “treatment” may include, in a given subject, one or more of the following: reducing the incidence or progression of AS, preventing the disease, reducing the severity of the symptoms of the disease, delaying its progression, eliminating the symptoms of the disease, slowing the progression of the disease, or increasing the effectiveness of the therapy.
[0093] The described therapy provides UBE3A isoform 1 expression to achieve the desired outcome, namely, the treatment of Angelman syndrome (AS) or one or more of its symptoms. Symptoms may include, but are not limited to, one of many, intellectual disability, speech impairment, ataxia, epilepsy, seizure disorder, microcephaly, psychomotor retardation, and hypotonia with hyperreflexia (see, for example, Buting K et al., incorporated herein by reference). See al., Angelman syndrome—insight into a rare neurogenetic disorder, Nat Rev Neurol, 2016, 12(10):584-593, epub September 12, 2016. As described herein, desired outcomes may include reduction or elimination of neurophysical complications, including developmental delay, intellectual disability, severe speech disorders, and motor and balance problems.
[0094] A “therapeutic amount” of a composition provided herein is delivered to a subject to achieve a desired result or reach a therapeutic goal. In one embodiment, the therapeutic goal for treating AS is to restore UBE3A isoform 1 expression in the patient’s neurons or in a population of neurons to a functional level that is within the normal range or at a non-AS level. In another embodiment, the therapeutic goal for treating AS is to increase UBE3A isoform 1 expression to at least about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 2%, and about 1% compared to a normal or non-AS level or a pre-treatment UBE3A expression level. Patients whose function has been rescued to below 100% activity levels by delivery of UBE3A isoform 1 may optionally receive further treatment. In another embodiment, the therapeutic goal for the treatment of AS is to increase UBE3A isoform 1 expression in a percentage of target neurons, including about 60%, 55%, 50%, 45%, 40%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 2%, or 1% of neurons in a selected population.
[0095] In certain embodiments, the foregoing provides a method for treating AS by administering an expression cassette, vector, or rAAV to a subject requiring UBE3A isoform 1 to induce functional expression of UBE3A isoform 1 in neurons. In certain embodiments, the method comprises delivering a nucleic acid sequence expressing UBE3A isoform 1 (the amino acid sequence of SEQ ID NO: 2).
[0096] In certain embodiments, the herein provides a method of enzyme supplementation by administering an expression cassette, vector, or rAAV providing UBE3a isoform 1 to a subject requiring such a service, thereby inducing the expression of functional UBE3a isoform 1 in neurons. In certain embodiments, the method includes delivering a nucleic acid sequence expressing UBE3a isoform 1 (the amino acid sequence of SEQ ID NO: 2). In certain embodiments, the herein provides a method of enzyme supplementation by administering an expression cassette, vector, or rAAV providing UBE3a isoform 3 to a subject requiring such a service, thereby inducing the expression of functional UBE3a isoform 3 in neurons. In certain embodiments, the method includes delivering a nucleic acid sequence expressing UBE3a isoform 3 (the amino acid sequence of SEQ ID NO: 21).
[0097] The gene therapies described herein, whether viral or nonviral, may be used in conjunction with other treatments (secondary therapies), i.e., standard care for the diagnosis and condition of the subject (patient). As used herein, the term “secondary therapy” refers to therapies that can be combined with the gene therapies described herein for the treatment of AS. In some embodiments, the gene therapies described herein may be combined with one or more secondary therapies for the treatment of AS, e.g., anticonvulsants or dietary restrictions (e.g., ketogenic drugs). It is administered in combination with the administration of (and hypoglycemia). Secondary therapy may be any therapy that helps prevent, stop, or alleviate these symptoms of AS. Secondary therapy may be administered before, concurrently with, or after the administration of the compositions described above. Subjects may, at the discretion of their physician, be permitted to continue their standard care therapy before and concurrently with gene therapy treatment. Alternatively, the physician may choose to discontinue standard care therapy before administering gene therapy treatment and, optionally, restart standard care therapy as adjunct therapy after administering gene therapy. In another embodiment, the gene therapy described herein may be combined with genotyping analysis or genetic screening which is routine in the art and may include the use of PCR to identify one or more mutations in the nucleic acid sequence of the UBE3A gene. As described above, subjects who exhibit symptoms of AS in early life (e.g., 1 to 3 months), as well as subjects diagnosed with AS in later life, are intended recipients of the compositions and methods described herein.
[0098] "Administering" or "administration route" means delivering the compositions described herein to a subject, with or without a pharmaceutical carrier or excipient. Administration routes may be combined if desired. In some embodiments, administration is repeated periodically. Continuous administration may mean a time gap between multiple administrations at intervals of days, weeks, months, or years. In one embodiment, the compositions described herein are administered to a subject one or more times. In one embodiment, multiple administrations are separated by days, weeks, months or years. In one embodiment, re-administration one, two, three or more times is permitted. Such re-administration may be by the same type of vector or by a different vector. In a further embodiment, the vectors described herein can be used alone or in combination with standard care for a patient's diagnosis and condition. The nucleic acid molecules and / or vectors described herein may be delivered in a single composition or in multiple compositions. Optionally, two or more different AAVs, or multiple viruses, may be delivered [see, e.g., WO2011 / 126808 and WO2013 / 049493].
[0099] In one embodiment, the expression cassettes, vectors, or other compositions described herein for gene therapy are delivered as a single dose per patient. In one embodiment, a subject is delivered a therapeutically effective amount of the compositions described herein. As used herein, "therapeutically effective amount" refers to the amount of an expression cassette or vector, or combination thereof.
[0100] In one embodiment, the expression cassette is delivered in the vector genome at an amount of about 1×10 9 genome copies (GC) per gram of brain mass, including all integers and decimals and endpoints within the range. In another embodiment, the dosage is 1×10 13 GC to about 1×10 10 GC per gram of brain mass. In certain embodiments, the dosage of the vector administered to a patient is at least about 1.0×10 13 GC.9 GC / g, approximately 1.5 × 10⁻⁶ 9 GC / g, approximately 2.0 × 10⁻⁶ 9 GC / g, approximately 2.5 × 10⁻⁶ 9 GC / g, approximately 3.0 × 10⁻⁶ 9 GC / g, approximately 3.5 × 10⁻⁶ 9 GC / g, approximately 4.0 × 10⁻⁶ 9 GC / g, approximately 4.5 × 10⁻⁶ 9 GC / g, approximately 5.0 × 10⁻⁶ 9 GC / g, approximately 5.5 × 10⁻⁶ 9 GC / g, approximately 6.0 × 10⁻⁶ 9 GC / g, approximately 6.5 × 10⁻⁶ 9 GC / g, approximately 7.0 × 10⁻⁶ 9 GC / g, approximately 7.5 × 10⁻⁶ 9 GC / g, approximately 8.0 × 10⁻⁶ 9 GC / g, approximately 8.5 × 10⁻⁶ 9 GC / g, approximately 9.0 × 10⁻⁶ 9 GC / g, approximately 9.5 × 10⁻⁶ 9 GC / g, approximately 1.0 × 10⁻⁶ 10 GC / g, approximately 1.5 × 10⁻⁶ 10 GC / g, approximately 2.0 × 10⁻⁶ 10 GC / g, approximately 2.5 × 10⁻⁶ 10 GC / g, approximately 3.0 × 10⁻⁶ 10 GC / g, approximately 3.5 × 10⁻⁶ 10 GC / g, approximately 4.0 × 10⁻⁶ 10 GC / g, approximately 4.5 × 10⁻⁶ 10 GC / g, approximately 5.0 × 10⁻⁶ 10 GC / g, approximately 5.5 × 10⁻⁶ 10 GC / g, approximately 6.0 × 10⁻⁶ 10 GC / g, approximately 6.5 × 10⁻⁶ 10 GC / g, approximately 7.0 × 10⁻⁶ 10 GC / g, approximately 7.5 × 10⁻⁶ 10 GC / g, approximately 8.0 × 10⁻⁶ 10 GC / g, approximately 8.5 × 10⁻⁶ 10 GC / g, approximately 9.0 × 10⁻⁶ 10 GC / g, approximately 9.5 × 10⁻⁶ 10 GC / g, approximately 1.0 × 10⁻⁶ 11 GC / g, approximately 1.5 × 10⁻⁶ 11 GC / g, approximately 2.0× 10 11 GC / g, approximately 2.5 × 10⁻⁶ 11GC / g, approximately 3.0 × 10⁻⁶ 11 GC / g, approximately 3.5 × 10⁻⁶ 11 GC / g, approximately 4.0 × 10⁻⁶ 11 GC / g, approximately 4.5 × 10⁻⁶ 11 GC / g, approximately 5.0 × 10⁻⁶ 11 GC / g, approximately 5.5 × 10⁻⁶ 11 GC / g, approximately 6.0 × 10⁻⁶ 11 GC / g, approximately 6.5 × 10⁻⁶ 11 GC / g, approximately 7.0 × 10⁻⁶ 11 GC / g, approximately 7.5 × 10⁻⁶ 11 GC / g, approximately 8.0 × 10⁻⁶ 11 GC / g, approximately 8.5 × 10⁻⁶ 11 GC / g, approximately 9.0 × 10⁻⁶ 11 GC / g, approximately 9.5 × 10⁻⁶ 11 GC / g, approximately 1.0 × 10⁻⁶ 12 GC / g, approximately 1.5 × 10⁻⁶ 12 GC / g, approximately 2.0 × 10⁻⁶ 12 GC / g, approximately 2.5 × 10⁻⁶ 12 GC / g, approximately 3.0 × 10⁻⁶ 12 GC / g, approximately 3.5 × 10⁻⁶ 12 GC / g, approximately 4.0 × 10⁻⁶ 12 GC / g, approximately 4.5 × 10⁻⁶ 12 GC / g, approximately 5.0 × 10⁻⁶ 12 GC / g, approximately 5.5 × 10⁻⁶ 12 GC / g, approximately 6.0 × 10⁻⁶ 12 GC / g, approximately 6.5 × 10⁻⁶ 12 GC / g, approximately 7.0 × 10⁻⁶ 12 GC / g, approximately 7.5 × 10⁻⁶ 12 GC / g, approximately 8.0 × 10⁻⁶ 12 GC / g, approximately 8.5 × 10⁻⁶ 12 GC / g, approximately 9.0 × 10⁻⁶ 12 GC / g, approximately 9.5 × 10⁻⁶ 12 GC / g, approximately 1.0 × 10⁻⁶ 13 GC / g, approximately 1.5 × 10⁻⁶ 13 GC / g, approximately 2.0 × 10⁻⁶ 13 GC / g, approximately 2.5 × 10⁻⁶ 13 GC / g, approximately 3.0 × 10⁻⁶ 13 GC / g, approximately 3.5 × 10⁻⁶ 13 GC / g, approximately 4.0 × 10⁻⁶ 13 GC / g, approximately 4.5 × 10⁻⁶ 13GC / g, approx. 5.0×10 13 GC / g, approx. 5.5×10 13 GC / g, approx. 6.0×10 13 GC / g, approx. 6.5×10 13 GC / g, approx. 7.0×10 13 GC / g, approx. 7.5×10 13 GC / g, approx. 8.0×10 13 GC / g, approx. 8.5×10 13 GC / g, approx. 9.0×10 13 GC / g, approx. 9.5×10 13 GC / g, or approximately 1.0 × 10⁻⁶ 14 This is GC / g brain mass.
[0101] In certain embodiments, the regimen may include additional treatment comprising a composition containing a gene editing system. See, for example, U.S. Patent Application No. 63 / 016,712, filed April 28, 2020, and U.S. Patent Application No. 63 / 118,299, filed November 25, 2020, both entitled “Compositions and uses for Treatment of Angelman Syndrome.” This treatment may precede treatment with the gene replacement therapy described herein and may utilize a vector having a different capsid than that used in the initial treatment. Further combinations of AAV capsids may be selected by those skilled in the art.
[0102] In certain embodiments, the therapeutic regimen may include the co-expression of UBE3A isoform 1 and UBE3A isoform 3. In certain embodiments, the therapeutic agent may include combination therapy of AAV.hUBE3A-isoform 1 and hUBE3A enzyme replacement therapy (e.g., with isoform 3 and / or isoform 1 enzyme). In certain embodiments, the therapeutic regimen may include co-therapy of an AAV.hUBE3A-isoform 1 gene therapy vector and an immunomodulatory regimen. Such immunomodulatory regimens may include, but are not limited to, glucocorticoids, steroids, antimetabolists, T-cell inhibitors, macrolides (e.g., rapamycin or rapalog), and immunosuppressants such as cell division inhibitors including alkylating agents, antimetabolists, cytotoxic antibiotics, antibodies, or agents active against immunophilins. Immunosuppressants may include nitrogen mustard, nitrosourea, platinum compounds, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, anthracyclines, mitomycin C, bleomycin, mitramycin, IL-2 receptor (CD25) specific antibodies or CD3 specific antibodies, anti-IL-2 antibodies, cyclosporine, tacrolimus, sirolimus, IFN-β, IFN-γ, opioids, or TNF-α (tumor necrosis factor-α) conjugates. In certain embodiments, immunosuppressive therapy may be initiated before gene therapy administration. Such therapy may involve the co-administration of two or more drugs (e.g., prednisolone, mycophenolate mofetil (MMF), and / or sirolimus (i.e., rapamycin)) on the same day. One or more of these drugs may be continued after gene therapy administration at the same or adjusted doses. Such therapy may last for approximately one week, 15 days, 30 days, 45 days, 60 days, or longer, as needed. Furthermore, other concurrent therapies may be used, for example, to deplete anti-AAV antibodies. The present invention may include an anti-IgG enzyme described as useful for (therefore enabling the administration of antibodies exceeding the threshold level of the selected AAV capsid to the patient under test), and / or delivery of an anti-FcRN antibody as described in, for example, U.S. Provisional Patent Application No. 63 / 040,381, filed on June 17, 2020, entitled “Compositions and Methods for Treatment of Gene Therapy Patients,” and / or one or more of the following: a) a steroid or combination of steroids, and / or (b) an IgG cleavage enzyme, c) an inhibitor of Fc-IgE binding, (d) an inhibitor of Fc-IgM binding, (e) an inhibitor of Fc-IgA binding, and / or (f) a gamma interferon.
[0103] Generally, the method involves administering a pharmaceutically effective amount of a composition to a mammalian subject requiring a pharmaceutically acceptable carrier, comprising a recombinant adeno-associated virus (AAV) carrying nucleic acid sequences encoding one or more elements of a UBE3A gene substitution (expression) system under the control of a regulatory sequence, and a pharmaceutically acceptable carrier. In one embodiment, such a method is designed to treat, delay, or halt the progression of AS in a mammalian subject.
[0104] In one embodiment, a method for treating AS is provided by administering a vector, rAAV, aqueous suspension, or pharmaceutical composition described herein to a subject requiring such treatment. In one embodiment, the rAAV is approximately 1 × 10⁻⁶ 10 ~Approx. 1×10 15 It is delivered at genome copy (GC) / kg body weight. In certain embodiments, the subject is human. In one embodiment, rAAV is administered in more than one dose. In further embodiments, rAAV is administered in divided doses over several days, weeks, months, or years. [Examples]
[0105] The present invention will now be described with reference to the following embodiments. These embodiments are provided for illustrative purposes only and should not be construed in any way as limiting the present invention to these embodiments, but rather as encompassing all variations that become apparent as a result of the teachings provided herein.
[0106] Angelman syndrome (AS) is a rare neurodevelopmental disorder affecting approximately 500,000 people worldwide. AS is characterized by intellectual and physical disabilities, sleep disturbances and disorders, and bowel dysfunction. Many of these defects are caused by the loss of the maternal ubiquitin protein ligase E3A (UBE3A) allele. Currently, treatment options for AS are limited. Gene replacement therapy based on AAV is a representative of promising strategies to restore UBE3A isoform expression and mitigate the severity of AS. However, the UBE3A gene encodes three isoforms, and it is currently unclear which UBE3A isoform is the most effective candidate. We investigated the efficacy of an AAV vector delivering an engineered human UBE3A isoform in a mouse model of AS (UBE3A m- / p+ This uncertainty is addressed by comparing the results in the following manner. Western blotting and immunohistochemical analysis showed that intracerebroventricular injection of AAV-UBE3A human isoform 1 and 2 vectors into neonatal controls and AS mice resulted in robust protein expression. Isoform 1 replacement significantly improved gait, nest-building ability, and motor coordination in AS mice in a dose-dependent manner. Unlike isoform 1, isoform 2 further impaired nest-building ability and motor coordination in AS mice. Toxicity studies in non-human primates suggest that no significant adverse effects were observed with high doses of AAV-UBE3A isoform 1 vector injected into the cisterna magna. In summary, these data suggest that the AAV-UBE3A isoform 1 vector is the most therapeutically effective due to its promising safety profile. These preclinical findings represent a significant step forward in the development of gene replacement therapies for AS.
[0107] Example 1 - Manipulated hUBE3A isoform 1 and manipulated hUBE3A isoform 2 coding sequences under the direction of a modified human synapsin promoter. In the first set of studies in mice, a series of plasmids containing engineered human UBE3A isoform 1 (SEQ ID NO: 9) or UBE3A isoform 2 (SEQ ID NO: 10) transgenes under the control of a modified human synapsin (hSyn) promoter (SEQ ID NO: 12) were engineered. To enhance transcriptional stability, an SV40 polyadenylated sequence (SEQ ID NO: 13) was included. The promoter-transgene-SV40 construct was facilitated with an inverted terminal repeat (ITR). The plasmids were packaged in PHP.B, an AAV9 variant that robustly transduced neurons and glial cells of the central nervous system in C57BL6 / J mice.
[0108] The coding sequence for the modified human synapsin promoter is provided as SEQ ID NO: 12.
[0109] The resulting vector genome is reproduced as SEQ ID NO: 3 (hSyn.hUbe3a-1.GSco.SV40) and SEQ ID NO: 7 (isoform 2hSyn.hUbe3a-2.GSco.SV40).
[0110] The AAVPHP.B capsid (US9,585,971) is generated in packaging host cells using triple transfection technology within a transplasmid containing the AAV2 rep coding sequence and the PHP.B VP1 coding sequence, and then co-transfected with a cis-plasmid containing the vector genome and a transplasmid expressing necessary adenovirus helper functions not provided by the packaging host cells.
[0111] Example 2 - rAAV-mediated delivery of hUBE3A to mice and NHP A. Expression studies of hUBE3A isoforms 1 and 2 in adult mouse brains AAV-PHP.B-synapsin-UBE3A isoform 1 and AAV-PHP.B-synapsin-UBE3A-isoform 2 vectors were injected (intraventricular-ICV) into the brains of wild-type adult mice, and the transgene expression was quantified by Western blotting to identify the one with the highest expression (Figure 8).
[0112] Methods: Adult wild-type WT (UBE3A m+ / p+ ) and UBE3A KO / null(UBE3A m- / p+ ) Delivered to littermates by retroorbital (IV) injection 5 x 10 11 GC / mouse. Brains were harvested 14 days after injection for Western blotting. Then, for optimal expression, cDNA was subcloned into a plasmid containing a completely intact ITR.
[0113] B. Determination of the most therapeutically effective AAV-UBE3A isoform vector. In a mouse model of AS, the ability of the highest-expressing AAV-PHP.B-synapsin-UBE3A-isoform 1 (isoform 1) and AAV-PHP.B-synapsin-UBE3A-isoform 2 (isoform 2) vectors to rescue motor and behavioral defects was directly compared. Neonatal wild-type or AS(UBE3A m- / p+ ) Mouse, 1 x 10 per animal 11 Either isoform 1 or isoform 2 vector was injected intraventricularly (ICV) at a dose equivalent to a genome copy. Behavioral tests were performed (8-10 weeks of age), in the following order: (1) catwalk, (2) spontaneous movement, (3) rotarod, and (4) nest building. After 2 months, AS mice injected with isoform 1 instead of isoform 2 showed statistically significant improvements in gait (stride length, Figures 11A-11D), nest building ability (Figures 10A and 10B), and motor coordination (Figures 9A and 9B). In fact, isoform 2 expression exacerbated the defect in nest building ability in AS mice (Figures 10C and 10D). 1 × 10⁶ per animal 10Injection of isoform 1 at low doses of genome copies showed low efficacy but improved nest-building ability in AS mice. Furthermore, isoform 1 in wild-type mice... Overexpression of UBE3A isoform 1 or 2 was observed to have adverse effects on several behavioral regions, highlighting the importance of strict control of UBE3A isoform expression. In summary, direct studies demonstrated that the nuclear UBE3A isoform 1 vector had higher therapeutic efficacy than the cytoplasmic isoform 2 vector in reducing behavioral defects in AS mice. The expression and localization of the manipulated human UBE3A isoform 1 protein were compared to wild-type UBE3A. m- / p+ Mice and treated UBE3A m- / p+ The neuronal marker NeuN and the nuclei were confirmed by immunofluorescence imaging in sagittal brain sections from mice (i.e., cortex, hippocampus, thalamus, hypothalamus, and midbrain) with co-staining of the nuclei. Visiopharm software was used to determine and quantify the percentage of UBE3A isoform 1 (Figures 5 and 6) and UBE3A isoform 2 (Figure 7) protein-positive neurons in different brain regions (Figures 5 and 6).
[0114] 1 x 10 10 At GC doses, administration of AAV-PHP.B-hSyn-UBE3A-isoform 1 achieved approximately 50% of wild-type endogenous UBE3A isoform expression, with no significant impact on spontaneous movement, motor coordination, or behavioral defects in nest building, and provided some improvement in gait abnormalities. Figure 5 shows treated UBE3A. m- / p+ This shows the quantification of UBE3A protein-positive neurons in mice (statistical analysis: mean ± SD, unpaired Student's t-test). The treatment involves 1 × 10⁻¹⁰ cellular stimuli via the intraventricular ventricle (ICV). 10 The administration included GC / animal doses of AAV-PHP.B-hSyn-UBE3A-isoform 1.
[0115] 1 x 10 11At high doses of GC, administration of AAV-PHP.B-hSyn-UBE3A-isoform 1 achieved approximately 100% wild-type endogenous UBE3A isoform expression and significantly improved nest-building ability (Figure 10A). Following the method described in Deacon RMJ, 2006, Assessing nest building in mice, Nat Protoc 1(3):1117-9, treated UBE3A m- / p+ Mice used significantly more nesting material to construct their nests (Figure 10B). Administration of UBE3A-isoform 1 did not affect the reduced activity state, however UBE3A mp+ In mice, gait abnormalities were normalized compared to previously published findings (Heck et al., Analysis of cerebellar function in Ube3a-deficient mice reveals genotype-specific (Leg length was evaluated as described in behaviors, 2008, Hum Mol Genetics, 17(14):2181-2189; epub April 15, 2008). UBE3A-isoform 1 administration (Figure 9A) was used instead of isoform 2 administration (Figure 9B). m- / p+ It significantly reduced motor coordination defects in mice. Figure 6 shows treated UBE3A. m- / p+ This shows the quantification of UBE3A protein-positive neurons in mice (statistical analysis: unpaired t-test). The treatment involves 1 × 10⁻¹⁰ cellular stimuli via the intraventricular ventricle (ICV). 11 The treatment consisted of administering AAV-PHP.B-hSyn-UBE3A-isoform 1 at GC / animal doses. The quantification of protein expression from Figure 5 is summarized in Table 1 below. [Table 1]
[0116] Therapeutic effects of UBE3A-isoform replacement: Isoform 1: (i) Correcting stride length (ii) normalization (clinically relevant gait defects), (ii) improvement of motor coordination, (iii) improvement of nest building behavior, (iv) UBE3 deficiency (UBE3A m- / p+ ) Does not affect the reduced spontaneous movement state in mice. Isoform 2: (i) Impairs nest-building behavior, and (ii) Does not affect the reduced spontaneous movement state (like Isoform 1) or motor coordination.
[0117] In addition, the data described above indicate that robust UBE3A isoform 1 protein expression was observed in the majority of neurons in several brain regions. UBE3A isoform 1 protein expression was dose-dependent, at 1 × 10⁻⁶ 10 For GC / animals, 1 × 10 11 In animals treated with GC / animals, the percentage of UBE3A-positive neurons was higher.
[0118] Preclinical studies in AS mice showed that AAV-PHP.B-synapsin-UBE3A-isoform 1 was well expressed and alleviated motor and behavioral defects in AS mice. Next, due to the similarity of the immune system and brain structure to humans, the therapeutic potential of the isoform 1 vector was investigated by evaluating its safety profile at high doses in rhesus monkeys. First, the AAV-hu68-synapsin-UBE3A-isoform 1 vector was generated. AAVhu68 is also an in-house developed AAV9 variant that functions well in non-human primates. The AAVhu68-hSyn-UBE3A-isoform 1 vector was added to the cerebrospinal fluid of the cisterna magna of three rhesus monkeys (NHP-1, NHP-2, NHP-3) in 3 × 10⁶ doses. 13High doses of GC / animals were injected. After 35 days, monkeys were captured and evaluated for transgene expression, immune response, and adverse effects. Cage lateral assessment revealed no animals with clinically significant conditions or neurological concerns. Blood chemistry tests showed normal coagulation, hepatic, and renal function in the treated monkeys. Low levels of isoform 1 vector were observed in the medulla and several brain regions, including the parietal and temporal cortices, and high levels in the dorsal root ganglia of the spine (Figure 2A). In addition, low-expression human UBE3A-isoform 1 mRNA was detected in several brain regions, including the dorsal root ganglia of the spine (Figures 2B and 2C). Localization of the manipulated human UBE3A isoform 1 transcript was confirmed by fluorescence imaging of the dorsal root ganglia (cervical, thoracic, and lumbar segments) from three treated NHP-derived monkeys. UBE3A isoform 1 transcript localization was determined using RNAscope probes specific to the manipulated human sequence (Figures 7A-7I) and counterstained with DAPI (nucleus). Images of the region of interest were taken at various magnifications, and a 20x magnification image is shown. Figures 7A-7I show fluorescence images of manipulated human UBE3A isoform 1 (hUBE3A-1) transcript localization in dorsal root ganglia (cervical, thoracic, and lumbar segments) from three treated non-human primate animals (NHP; 35-day study). Treatment was mediated via the cisterna magna (ICM) pathway, resulting in 3 × 10⁻¹⁴ septal changes. 13The study included administration of AAV-hu68-hSyn-UBE3A-isoform 1 at GC / animal doses. Images of the target region are shown at 20x magnification. Figure 7A shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the cervical spinal segment of the dorsal root ganglion derived from NHP-1. Figure 7B shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the cervical spinal segment of the dorsal root ganglion derived from NHP-2. Figure 7C shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the cervical spinal segment of the dorsal root ganglion derived from NHP-3. Figure 7D shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the thoracic spinal segment of the dorsal root ganglion derived from NHP-1. Figure 7E shows fluorescence imaging of manipulated hUBE3A-1 transcript localization in the thoracic spinal segment of the dorsal root ganglion derived from NHP-2. Figure 7F shows fluorescence imaging of the localization of the manipulated hUBE3A-1 transcript in the thoracic spinal segment of the dorsal root ganglion derived from NHP-3. Figure 7G shows fluorescence imaging of the localization of the manipulated hUBE3A-1 transcript in the lumbar spinal segment of the dorsal root ganglion derived from NHP-1. Figure 7H shows fluorescence imaging of the localization of the manipulated hUBE3A-1 transcript in the lumbar spinal segment of the dorsal root ganglion derived from NHP-2. Figure 7I shows fluorescence imaging of the localization of the manipulated hUBE3A-1 transcript in the lumbar spinal segment of the dorsal root ganglion derived from NHP-3.
[0119] The immune response was minimal, and ELISPOT analysis showed a moderate immune response to the hu68 capsid, as expected. Finally, dorsal root ganglion (DRG) toxicity is a concern for central nervous system-targeted and high-dose AAV in non-human primates and potentially in humans. However, mild DRG (Figures 12-12C) and neuronal toxicity were observed in the spinal cord (Figures 13A-13C) and peripheral nerves (Figures 13A-13C) of only one animal. In summary, these findings suggest that high-dose ICM delivery of the AAV hu68-hSyn-UBE3A-isoform 1 vector was well tolerated in non-human primates. In addition, conclusions from this dataset, consistent with pPCR analysis, show that robust UBE3A isoform 1 transcript localization could be detected in all DRG segments. In treated NHP, there was no significant AAV toxicity despite robust transgene DRG expression.
[0120] Example 3 - NHP pilot study investigating the safety and expression of the hUBE3A isoform 1±miR183 target sequence in rhesus monkeys Due to concerns regarding high-dose AAV-induced DRG toxicity in non-human primates and humans, a microRNA strategy was employed to simultaneously downregulate isoform 1 protein expression in DRGs and thus mitigate DRG toxicity. Including the miR183 target site in the 3' UTR of the transgene (in this case, UBE3A-isoform 1) selectively promotes RISC complex-mediated degradation of isoform 1 transgene mRNA in sensory neurons of DRGs while maintaining therapeutic transgene expression in target neurons in the brain. Four copies of the miR183 binding site were inserted between the 3' end of the most highly expressed manipulated isoform 1 or isoform 2 and the SV40 polyadenylation site and packaged in an AAVhu68 capsid. Sequence ID 11 provides the sequence of one copy of the miRNA183 (or miR183) targeting sequence. In this manner, AAV-hu68-synapsin-UBE3A-isoform 1-4xmiR183 was generated. The AAVhu68 capsid is generated in packaging host cells using triple transfection technology within a transplasmid containing the AAV2 rep coding sequence and the hu68 VP1 coding sequence of SEQ ID NO: 14, and then co-transfected with a cis-plasmid containing the vector genome and a transplasmid expressing necessary adenovirus helper functions not provided by the packaging host cells.
[0121] Including 4×miR183 cassettes means adult wild type or 1×10 11 In AS mice administered intravenously at GC / animal doses, there was no significant effect on UBE3A-isoform 1 or isoform 2 protein expression.
[0122] Next, the safety and expression profile of the rAAVhu68-synapsin-UBE3A-isoform1-4xmiR183 vector in rhesus monkeys were compared with the rAAVhu68-synapsin-UBE3A-isoform1-miR183 vector previously analyzed. AAV-hu68-synapsin-UBE3A-isoform1-4xmiR183 was expressed in 3 × 10⁻¹⁴ units. 13The vector was injected into the cisterna magna of three monkeys using GC / animals, and the monkeys were captured 35 days later for analysis. All animals were clinically normal throughout the study period. As expected, low levels of isoform 1-miR183 vector were observed in several brain regions, including the medulla, with higher levels in the dorsal root ganglia and spinal cord. In addition, low human isoform 1-miR183 mRNA expression was detected in the dorsal root ganglia and spinal cord, which was often comparable to isoform 1. Like isoform 1, isoform 1-miR183 was well tolerated in non-human primates, exhibited only slight immunogenicity, and did not affect coagulation, hepatic, or renal function. Similarly, no significant DRG or neurotoxicity was observed in monkeys treated with isoform 1-miR183. See Figures 3A-3B. rAAVhu68.synapsin- in peripheral nerves. The effects of UBE3A-isoform 1 are shown in Figures 4A-4B.
[0123] The vector biodistribution and mRNA expression were evaluated and are shown in Figures 2A-2C.
[0124] In summary, these findings suggest that high-dose ICM delivery of the AAVhu68-hSyn-UBE3A-isoform1-miR183 vector was well tolerated in non-human primates. While this vector is not useful in non-human primates, it may be useful in human clinical trials to mitigate DRG and neuronal toxicity. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13]
[0125] All documents cited herein are incorporated herein by reference. The sequence listing filed with this specification under the name "21-9579PCT_SeqListing_ST25," and the sequences and texts therein, are incorporated herein by reference. U.S. Provisional Application No. 63 / 119,860, filed 1 December 2020, and U.S. Provisional Application No. 63 / 179,807, filed 26 April 2021, are incorporated herein by reference. While the present invention has been described with reference to certain embodiments, it will be understood that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.
Claims
1. 1. A composition comprising a stock of recombinant adeno-associated virus (rAAV) useful for treating Angelman Syndrome (AS), said rAAV comprising an AAV capsid and a vector genome packaged therein, said vector genome comprising: (a) AAV 5' inverted terminal repeat (ITR), (b) a UBE3A nucleic acid sequence comprising SEQ ID NO:9, or a sequence encoding a UBE3A isoform 1 protein at least 95% identical thereto (SEQ ID NO:2), said nucleic acid sequence being operably linked to a regulatory element that regulates expression of said UBE3A protein in a human cell; (c) a regulatory element that directs expression of the UBE3A of (b), and (d) a composition comprising an AAV 3'ITR.
2. the regulatory element comprises a neuron-specific promoter; Optionally, the neuron-specific promoter is a synapsin promoter; Optionally, the synapsin promoter is a truncated promoter having the nucleic acid sequence of SEQ ID NO:
12. The composition of claim 1.
3. The composition of claim 1 , wherein the regulatory element comprises a constitutive promoter.
4. The composition of any one of claims 1 to 3, wherein the regulatory elements further comprise one or more enhancers and one or more introns.
5. The regulatory sequence further comprises one or more targeting sequences of miRs in the dorsal root ganglion selected from miR182 and / or miR183; the targeting sequence is operably linked to and / or located downstream of the UBE3A nucleic acid sequence; The composition according to any one of claims 1 to 4.
6. The regulatory sequence is (a) further comprising four targeting sequences for miR183, said targeting sequences being located downstream of said UBE3A nucleic acid sequence; and / or (b) comprising four copies of SEQ ID NO:11; The composition according to any one of claims 1 to 5.
7. the AAV capsid is an AAVhu68 capsid, Optionally, the AAV capsid is an AAVhu68 capsid produced from expression of the nucleic acid sequence of SEQ ID NO:14 or SEQ ID NO:
16. The composition according to any one of claims 1 to 6.
8. the AAV capsid is an AAVrh91 capsid, Optionally, the AAV capsid is an AAVrh91 capsid produced from expression of a nucleic acid sequence of SEQ ID NO:17 or SEQ ID NO:
19. The composition according to any one of claims 1 to 6.
9. The composition of any one of claims 1 to 8, which is an aqueous suspension further comprising a physiologically compatible carrier, buffer, adjuvant, and / or diluent.
10. A composition according to any one of claims 1 to 9 for use in treating a patient with Angelman Syndrome.
11. A composition according to any one of claims 1 to 9 for use in the treatment of one or more symptoms of Angelman Syndrome.
12. 10. The composition of any one of claims 1 to 9 for use in treating one or more symptoms of Angelman syndrome in a patient having deficient neuronal UBE3A expression.
13. 13. The composition of claim 11 or 12, wherein the symptoms are selected from one or more of developmental delay, intellectual disability, severe speech impairment, ataxia, and / or epilepsy.
14. The composition of any one of claims 1 to 13, wherein the composition is delivered intrathecally to the patient.
15. The patient has at least 1×10 10 ~1×10 13 The composition of any one of claims 10 to 13, wherein the rAAV is injected at GC / kg.
16. A recombinant adeno-associated virus (rAAV) comprising an AAV capsid and a vector genome packaged therein, the vector genome comprising: (a) AAV 5' inverted terminal repeat (ITR), (b) a UBE3A nucleic acid sequence comprising SEQ ID NO:9, or a sequence at least 95% identical thereto, encoding UBE3A isoform 1 protein (SEQ ID NO:2), wherein said nucleic acid sequence is operably linked to a regulatory element that regulates expression of said UBE3A protein in a human cell; (c) a regulatory element that directs expression of the UBE3A of (b), and (d) AAV 3'ITR The rAAV comprising:
17. A composition according to any one of claims 1 to 9 or an rAAV according to claim 16 for the preparation of a medicament for treating Angelman syndrome and / or one or more symptoms of Angelman syndrome in a patient having deficient UBE3A expression in neurons.
18. A recombinant nucleic acid molecule comprising a vector genome, the vector genome comprising: (a) AAV 5' inverted terminal repeat (ITR), (b) a UBE3A nucleic acid sequence comprising SEQ ID NO:9, or a sequence at least 95% identical thereto, encoding UBE3A isoform 1 protein (SEQ ID NO:2), wherein said nucleic acid sequence is operably linked to a regulatory element that regulates expression of said UBE3A protein in a human cell; (c) a regulatory element that directs expression of the UBE3A of (b), and (d) AAV 3'ITR The recombinant nucleic acid molecule comprising:
19. A vector comprising an expression cassette comprising a UBE3A nucleic acid sequence comprising SEQ ID NO:9, or a sequence at least 95% identical thereto, encoding UBE3A isoform 1 protein (SEQ ID NO:2), wherein the nucleic acid sequence is operably linked to a regulatory element that regulates expression of the UBE3A protein in a human cell, and optionally the vector is a non-viral vector or a viral vector.
20. A plasmid comprising the recombinant nucleic acid molecule of claim 18.
21. A method for producing recombinant adeno-associated virus (rAAV) particles in a packaging host cell, the method comprising culturing the packaging host cell containing (a) a recombinant nucleic acid molecule of claim 18, (b) a recombinant nucleic acid molecule encoding an AAV rep protein, (c) a recombinant nucleic acid molecule encoding an AAV capsid, and (d) helper sequences sufficient to package an expression cassette into the AAV capsid, wherein the packaging host cell expresses the rep proteins and capsid proteins and packages the expression cassette into assembled capsids to produce the rAAV particles.
22. A pharmaceutical composition comprising a pharma- ceutically acceptable carrier and (a) the vector described in claim 19 or (b) the rAAV described in claim 16.
